Научная электронная библиотека
Монографии, изданные в издательстве Российской Академии Естествознания

ПАРАТГОРМОН-РОДСТВЕННЫЙ ПРОТЕИН. 2-е издание переработанное и дополненное

Курзанов А. Н., Ледванов М. Ю., Быков И. М., Медведев В. Л., Стрыгина Е. А., Бизенкова М. Н., Заболотских Н. В., Ковалев Д. В., Стукова Н. Ю.,

Литература к главе 14

1. Aaltomaa S., Lipponen P., Syrjanen K. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res. 1993 Mar-Apr; 13 (2): 533-8.

2. Akhtari M., Mansuri J., Newman K.A., Guise T.M., Seth P. Biology of breast cancer bone metastasis. Cancer Biol Ther. 2008; 7: 3–9. doi: 10.4161/cbt.7.1.5163.

3. Akino K., Ohtsuru A., Kanda K., Yasuda A., Yamamoto T., Akino Y., Naito S., Kurokawa M., Iwahori N., Yamashita S. Parathyroid hormone-related peptide is a potent tumor angiogenic factor. Endocrinology. 2000; 141: 4313-4316.

4. Alarmo E., Huhtala H., Korhonen T., Pylkkanen L., Holli K., Kuukasjarvi T., Parkkila S., Kallioniemi A. Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development. Mod Pathol. 2013; 26, 10–21. doi: 10.1038/modpathol.2012.128.

5. Alarmo E.L., Kallioniemi A. Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?Endocrine-Related Cancer. 2010; 17 (2): R123–R139. doi: 10.1677/ERC-09-0273.

6. Allinen M., Beroukhim R., Cai L., Brennan C., Lahti-Domenici J., Huang H., Porter D., Hu M., Chin L., Richardson A., Schnitt S., Sellers W.R., Polyak K. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell. 2004; 6 (1): 17–32. doi: 10.1016/j.ccr.2004.06.010.

7. Alokail M.S. The role of PTHrP in mitogenic signaling via EGFR-dependent pathways in breast cancer cells. Mol. Cell. Pharmacol. 2009; 1: 278–289.

8. Antoniou A.C., Kuchenbaecker K.B., Soucy P., Beesley ., Chen X., McGuffog L. et al., Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. Breast Cancer Res. 2012; 14 (1):R33. doi: 10.1186/bcr3121.

9. Ardeshirpour L., Brian S., Dann P., VanHouten J., Wysolmerski J. Increased PTHrP and decreased estrogens alter bone turnover but do not reproduce the full effects of lactation on the skeleton. Endocrinology. 2010; 151 (12): 5591-5601. doi: 10.1210/en.2010-0566.

10. Ardeshirpour L., Dann P., Adams D.J., Nelson T., VanHouten J., Horowitz M.C., Wysolmerski J.J. Weaning triggers a decrease in receptor activator of nuclear factor-kappaB ligand expression, widespread osteoclast apoptosis, and rapid recovery of bone mass after lactation in mice. Endocrinology 2007; 148: 3875–3886.

11. Ardeshirpour L., Dann P., Pollak M., Wysolmerski J., VanHouten J. The calcium-sensing receptor regulates PTHrP production and calcium transport in the lactating mammary gland. Bone. 2006; 38 (6): 787–793.

12. Assaker G., Camirand A., Abdulkarim B. et al., Identif?cation of PTHrP as a biomarker of short survival & brain metastasis in a tissue microarray retrospective analysis of triple-negative breast cancer [abstract]. In Proceedings of the 109th annual meeting of the American Association for Cancer Research; April 14–18. Chicago, IL: AACR. Abstract № 2632. Cancer Research. 2018a; 78 (13 Supplement): 2632-2632.

13. Assaker G., Camirand A., Sabri S. et al., In silico gene expression analysis of PTHrP and its association with molecular subtypes and organ-specif?c metastasis in human triple-negative breast cancer [abstract]. In Proceedings of the 109th annual meeting of the American Association for Cancer Research; April 14–18. Chicago, IL: AACR. Abstract № 2598. Cancer Research. 2018b; 78 (13 Supplement): 2598-2598.

14. Awolaran O., Brooks S.A., Lavender V. Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence. Breast. 2016 Dec; 30: 156-171. doi: 10.1016/j.breast.2016.09.017.

15. Azim H.A., Kamal N.S., Azim H.A. Jr. Bone metastasis in breast cancer: the story of RANK-ligand. J. Egypt. Natl. Canc. Inst. 2012; 24: 107–14. doi: 10.1016/j.jnci.2012.06.002.

16. Bandyopadhyay A., Nichols R.W., Wang L, et al., Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res. 2006; 66: 6714–21.

17. Barlet J.P., Champredon C., Coxam V., Davicco M.J., Tressol J.C. Parathyroid hormone-related peptide might stimulate calcium secretion into the milk of goats. J. Endocrinol. 1992; 132: 353–359.

18. Barnes G.L., Hebert K.E., Kamal M., Javed A., Einhorn T.A., Lian J.B., Stein G.S., Gerstenfeld L.C. Fidelity of Runx2 activity in breast cancer cells is required for the generation of metastases associated osteolytic disease. Cancer Res. 2004; 64: 4506–4513.

19. Bauman D.E., Currie W.B. Partitioning of nutrients during pregnancy and lactation: A review of mechanisms involving homeostasis and homeorhesis. J. Dairy Sci. 1980; 63 (9): 1514–1529. doi: 10.3168/jds.S0022-0302 (80) 83111-0.

20. Bendre M., Gaddy D., Nicholas R.W., Suva L.J. Breast cancer metastasis to bone: it is not all about PTHrP. Clin Orthop Relat Res. 2003; (415 Suppl): S39-45.

21. Bendre M.S., Gaddy-Kurten D., Mon-Foote T. et al., Expression of interleukin 8 and not parathyroid hormone-related protein by human breast cancer cells correlates with bone metastasis in vivo. Cancer Res 2002; 62: 5571–9.

22. Bergh J. Clinical studies of p53 in treatment and benefit of breast cancer patients. Endocr Relat Cancer. 1999 Mar; 6 (1): 51-9.

23. Binnerts M.E., Kim K.A., Bright J.M., Patel S.M., Tran K., Zhou M., Leung J.M., Liu Y., Lomas W.E. 3rd., Dixon M. et al. (2007). R-Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc. Natl. Acad. Sci. USA. 2007; 104: 14700-14705.

24. Birch M.A., Carron J.A., Scott M., Fraser W.D. and Gallagher J.A. Parathyroid hormone (PTH)/PTH-related protein (PTHrP) receptor expression and mitogenic responses in human breast cancer celi lunes. Br J Cancer. 1995; 72: pp. 90-95.

25. Blyth K., Cameron E.R., Neil J.C. The runx genes: gain or loss of function in cancer. Nat Rev Cancer. 2005; 5: 376–387.

26. Bohn O.L., Nasir I., Brufsky A., Tseng G.C., Bhargava R., MacManus K., Chivukula M. Biomarker profile in breast carcinomas presenting with bone metastasis. Int J Clin Exp Pathol. 2010; 3 (2): 139–146.

27. Bolzetta F., Veronese N., De Rui M., Berton L., Carraro S., Pizzato S., Girotti G., De Ronch I., Manzato E., Coin A. et al., Duration of breastfeeding as a risk factor for vertebral fractures. Bone. 2014; 68: 41–45. doi: 10.1016/j.bone.2014.08.001.

28. Booher C., Hood W. Calcium utilization during reproduction in big brown bats (Eptesicus fuscus). J Mammal. 2010; 91: 952–959. 10.1644/09-MAMM-A-186.1.

29. Boras-Granic K., Wysolmerski J.J. PTHrP and breast cancer: more than hypercalcemia and bone metastases. Breast Cancer Res. 2012; 14 (2): 307.

30. Boras-Granic K., Chang H., Grosschedl R., Hamel P.A. Lef1 is required for the transition of Wnt signaling from mesenchymal to epithelial cells in the mouse embryonic mammary gland. Dev Biol. 2006; 295 (1): 219–231.

31. Boras-Granic K., Van Houten J., Hiremath M. et al., Parathyroid hormone-related protein is not required for normal ductal oralveolar development in the post-natal mammary gland. PLoS One. 2011; 6: e27278.

32. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., Minn A.J., van de Vijver M.J., Gerald W.L., Foekens J.A., Massague. Genes that mediate breast cancer metastasis to the brain. Nature. 2009; 459: 1005–1009. doi: 10.1038/nature08021.

33. Bouizar Z., Spyratos F., Deytieux S., de Vernejoul C.M., Jullienne A. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases. Cancer Res 1993;. 53 (21): 5076-5078.

34. Bouizar Z., Spyratos F. and De Vernejoul M.C. The parathyroid hormonerelatedprotein (PTHrP) gene: Use of downstream TATA promotor and PTHrP1–139 coding pathways in primary breast cancers vary with the occurrence of bone metastasis. J Bone Miner Res. 1999; 14: pp.406–414.

35. Braude S., Graham A., Mitchell D. Lymphoedema/hypercalcaemia syndrome mediated by parathyroid-hormone-related protein. Lancet 1991; 337: 140-141.

36. Braun S., Vogl F.D., Naume B. et al., A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353: 793–802.

37. Brown E.M., Gamba G., Riccardi D. et al., Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature. 1993; 366 (6455): 575–580.

38. Brown E.M., MacLeod R.J. Extracellular calcium sensing and extracellular calcium signaling. Physiol Rev. 2001; 81 (1): 239–297.

39. Brown E.M. Extracellular Ca2+ sensing, regulation of parathyroid cell function, and role of Ca2+ and other ions as extracellular (first) messengers. Physiol. Rev. 1991; 71: 371-411.

40. Brundred N.J., Walker R.A., Ratciiffe W.A., Warwick J., Morrison J.M., Ratcliffe J.G. Parathyroi d hormone related protein and skeietai morbidity in breast cancer. Eur J Cancer. 1992; 28: pp.690–692.

41. Bucht E., Rong H., Bremme K., Granberg B., Rian E., Torring O. Midmolecular parathyroid hormone-related peptide in serum during pregnancy, lactation and in umbilical cord blood. Eur. J. Endocrinol. 1995; 132: 438-443.

42. Budayr A.A., Halbran B.P., King J.C., Diep D., Nissenson R.A. and Strewler G.J. High levels of a parathyroid hormone-like protein in milk. Proc Natl Acad Sci U S A. 1989; 86: pp.7183-7185.

43. Bueno-de-Mesquita J.M., Sonke G.S., van de Vijver M.J., Linn S.C: Additional value and potential use of the 70-gene prognosis signature in node-negative breast cancer in daily clinical practice. Annals of oncology. 2009; 22 (9), 2021–2030.

44. Bundred N.J., Walker R.A., Ratcliffe W.A., Warwick J., Morrison J.M., Ratcliffe J.G. Parathyroid hormone related protein and skeletal morbidity in breast cancer. Eur J Cancer 1992; 28: 690–2.

45. Burtis W.J., Bady T.F., Orloff J.J., Ersbak J.B., Warrell R.P., Olson B.R., Wu T.L., Mitnick M.E., Broadus A.E., Stewart A.F. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med.1990; 322: pp.1106–1112.

46. Burtis W.J., Fodero J.P., Gaich G., Debeyssey M., Stewart A.F. Preliminary characterization of circulating amino- and carboxy-terminal fragments of parathyroid hormone-related peptide in humoral hypercalcemia of malignancy. J ClinEndocrinolMetab. 1992; 75:pp.1110–1114.

47. Bussard K.M., Venzon D.J., Mastro A.M. Osteoblasts are a major source of inflammatory cytokines in the tumor microenvironment of bone metastatic breast cancer. Journal of Cellular Biochemistry. 2010; 111 (5): 1138–1148. doi: 10.1002/jcb.22799.

48. Bussard K.M., Gay C.V., Mastro A.M. The bone microenvironment in metastasis; what is special about bone?Cancer Metastasis Rev. 2007; 27: 41–55.

49. Cabioglu N., Yazici M.S., Arun B., Broglio K.R., Hortobagyi G.N., Price J.E., Sahin A. CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res. 2005; 11: 5686–5693. doi: 10.1158/1078-0432.CCR-05-0014.

50. Cai Q., Zhang B., Sung H., Low S.K., Kweon S.S., Lu W. et al., Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nature genetics. 2014; 46 (8): 886–90.

51. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012 Oct 4; 490 (7418): 61-70. doi: 10.1038/nature11412.

52. Canul-Medina G., Fernandez-Mejia C. Morphological, hormonal, and molecular changes in different maternal tissues during lactation and post-lactation. J Physiol Sci. 2019; 69 (3): 825–835. https://doi.org/10.1007/s12576-019-00714-4.

53. Cao G., Gu Z., Ren Y. Shu L., Tao C., Karaplis A., Goltzman D., Miao D. Parathyroid hormone contributes to regulating milk calcium content and modulates neonatal bone formation cooperatively with calcium. Endocrinology. 2009; 150: 561-569.

54. Caplan R.H., Wickus G.G., Sloane K., Silva P.D. Serum parathyroid hormone-related protein levels during lactation. J. Reprod. Med. 1995; 40: 216-218.

55. Care A.D., Abbas S.K., Ousey J., Johnson L. The relationship between the concentration of ionised calcium and parathyroid hormone-related protein (PTHrP[1–34]) in the milk of mares. Equine Vet. J. 1997; 29: 186-189.

56. Carron J.A., Fraser W.D., Gallagher J.A. PTHrP and the PTH/PTHrP receptor are co-expressed in human breast and colon tumours. Br. J. Cancer. 1997; 76: 1095-1098.

57. Cataisson C., Gordon J., Roussiere M., Abdalkhani A. Lindemann R., Dittmer J., Foley J., Bouizar Z. Ets-1 Activates Parathyroid Hormone-Related Protein Gene Expression In Tumorigenic Breast Epithelial Cells. Molecular and Cellular Endocrinology. 2003; 204: 155-168.

58. Cataisson C., Lieberherr M., Cotton J., Calvo F., Cros M., de Vernejoul M.C., Foley J., Bouizar Z. Parathyroid hormone-related peptide stimulates proliferation of highly tumorigenic human SV40-immortalized breast epithelial cells. J Bone Miner Res. 2000; 15: 2129-2139.

59. Chakravarti B., Chattopadhyay N., Brown E.M. Signaling through the extracellular calcium-sensing receptor (CaSR). Adv Exp Med Biol. 2012; 740: 103–142.

60. Chambers A.F., Groom A.C., MacDonald I.C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2002; 2 (8): 563–572.

61. Chano T., Ikebuchi K., Tomita Y., Jin Y., Inaji H., Ishitobi M., Teramoto K., Ochi Y., Tameno H., Nishimura I. et al., RB1CC1 together with RB1 and p53 predicts long-term survival in Japanese breast cancer patients. PLoS One. 2010; 5:e15737. doi: 10.1371/journal.pone.0015737.

62. Chattopadhyay N., Mithal A., Brown E.M. The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr. Rev. 1996; 17: 289–307.

63. Chen W., Hoffmann A.D., Liu H., Liu X. Organotropism: new insights into molecular mechanisms of breast cancer metastasis. NPJ Precision Oncology. 2018; 2 (4) doi: 10.1038/s41698-018-0047-0.

64. Chen W.Z., Shen J.F., Zhou Y., Chen X.Y., Liu J.M., Liu Z.L. Clinical characteristics and risk factors for developing bone metastases in patients with breast cancer. Sci Rep. 2017 Sep 12; 7 (1): 11325. doi: 10.1038/s41598-017–11700-4.

65. Cheng I., Klingensmith M.E., Chattopadhyay N., Kifor O., Butters R.R., Soybel D.I., Brown E.M. Identification and localization of the extracellular calcium-sensing receptor in human breast. J Clin Endocrinol Metab. 1998; 83 (2): 703–707.

66. Cheung V., Bouralexis S., Gillespie M.T. PTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL. PLoS One. 2013; 8 (6): e66343. doi: 10.1371/journal.pone.0066343.

67. Chiechi A., Waning D.L., Stayrook K.R., Buijs J.T., Guise T.A., Mohammad K.S. Role of TGF-? in breast cancer bone metastases. Adv. Biosci. Biotechnol. 2013; 4: 15–30. doi: 10.4236/abb.2013.410A4003.

68. Chilco P.J., Leopold V., Zajac J.D. Differential regulation of the parathyroid hormone-related protein gene P1 and P3 promoters by cAMP, Mol. Cell Endocrinol. 1998; 138: 173–184.

69. Chinni S.R., Sivalogan S., Dong Z., Filho J.C., Deng X., Bonfil R.D., Cher M.L. CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: The role of bone microenvironment-associated CXCL12. Prostate. 2006; 66 (1): 32–48. doi: 10.1002/pros.20318.

70. Chu E.Y., Hens J., Andl T., Kairo A., Yamaguchi T.P., Brisken C., Glick A., Wysolmerski J.J., Millar S.E. Canonical WNT signaling promotes mammary placode development and is essential for initiation of mammary gland morphogenesis. Development.2004; 131, 4819-4829.

71. Chu J.S., Huang C.S., Chang K.J. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in invasive ductal carcinoma of the breast in Taiwan. Cancer Lett. 1998 Sep 25; 131 (2): 145-52.

72. Clohisy D.R., Perkins S.L., Ranmaraine M.L. Review of cellular mechanisms of tumor osteolysis. Clin Orthop 2000; 373: 104–14.

73. Coleman R., Brown J., Terpos E., Lipton A., Smith M.R., Cook R., Major P. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev. 2008; 34 (7): 629–639. doi: 10.1016/j.ctrv.2008.05.001.

74. Coleman R. Treatment of metastatic bone disease and the emerging role of radium-223. Seminars in Nuclear Medicine. 2016; 46 (2): 99–104. doi: 10.1053/j.semnuclmed.2015.10.012.

75. Coleman R.E., Lipton A., Roodman G.D., Guise T.A., Boyce B.F., Brufsky A.M., Clezardin P., Croucher P.I., Gralow J.R., Hadji P., Holen I., Mundy G.R., Smith M.R., Suva L.J. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010; 36 (8): 615–620. doi: 10.1016/j.ctrv.2010.04.003.

76. Coleman R.E., Smith P., Rubens R.D. Clinical course and prognostic factors following bone recurrence from breast cancer. Br. J. Cancer. 1998; 77: 336–340. doi: 10.1038/bjc.1998.52.

77. Coleman R.E. Adjuvant bisphosphonates in breast cancer: Are we witnessing the emergence of a new therapeutic strategy? Eur. J. Cancer 2009; 45: 1909–1915.

78. Coleman R.E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res.2006; 12: 6243–6249.

79. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987; 55: 61-66.

80. Colloton M., Shatzen E., Wiemann B. et al., Cinacalcet attenuates hypercalcemia observed in mice bearing either Rice H-500 Leydig cell or C26-DCT colon tumors. European Journal of Pharmacology. 2013; 712 (1–3): 8–15. doi: 10.1016/j.ejphar.2013.04.013.

81. Cooke-Hubley S., Gao Z., Mugford G., Kaiser S.M., Goltzman D., Leslie W.D., Davison K.S., Brown J.P., Probyn L., Lentle B., Prior J.C., Kovacs C.S. Parity and lactation are not associated with incident fragility fractures or radiographic vertebral fractures over 16 years of follow-up: Canadian Multicentre Osteoporosis Study (CaMos). Arch Osteoporos. 2019 Apr 29; 14 (1): 49. doi: 10.1007/s11657-019-0601-6.

82. Cormier S., Delezoide A.L., Silve C. Expression patterns of parathyroid hormone-related peptide (PTHrP) and parathyroid hormone receptor type 1 (PTHR1) during human development are suggestive of roles specific for each gene that are not mediated through the PTHrP/PTHR1 paracrine signaling pathway. Gene Expr Patterns. 2003; 3: 59–63.

83. Cowin P., Wysolmerski J. Molecular mechanisms guiding embryonic mammary gland development. Cold Spring Harb. Perspect. Biol. 2010 Jun; 2 (6):a003251. doi: 10.1101/cshperspect.a003251.

84. Cros M., Cataisson C., Mee Cho Y., Berthois Y., Bernard-Poenaru O., Denne M., Graulet A.M., deVernejoul M.C., Bouizar Z. Constitutive production of ParathyroiHormone Related Protein (PTHrP) by fibroblasts derivated from normal and pathological human tumorigenic breast cancer. Oncol.Res/Anti-Cancer Drug Design. 2002; 13: 137–146.

85. Cross B.M., Hack A., Reinhardt T.A., Rao R. SPCA2 regulates Orai1 trafficking and store independent Ca2+ entry in a model of lactation. PLoS One. 2013 Jun 28; 8 (6):e67348. doi: 10.1371/journal.pone.0067348.

86. Cross N.A., Hillman L.S., Allen S.H., Krause G.F., Vieira N.E., Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study, The American Journal of Clinical Nutrition. 1995a; 61 (3): 514–523. doi.org/10.1093/ajcn/61.3.514.

87. Cross N.A., Hillman L.S., Allen S.H., Krause G.F. Changes in bone mineral density and markers of bone remodeling during lactation and postweaning in women consuming high amounts of calcium. J Bone Miner Res. 1995b; 10 (9): 1312–1320.

88. Cross N.A., Hillman L.S., Forte L.R. The effects of calcium supplementation, duration of lactation, and time of day on concentrations of parathyroid hormone-related protein in human milk: A pilot study. J Hum Lact. 1998; 14: 111–117.

89. Daniel C.W., Silberstein G.B. Postnatal development of the rodent mammary gland. In The mammary gland: development, regulation, and function. M.C. Neville and C.W. Daniel, editors. Plenum Press. New York, New York, USA. 1987; 3–36.

90. Datta N.S., Abou-Samra A.B. PTH and PTHrP signaling in osteoblasts. Cell. Signal. 2009; 21 (8): 1245–1254. doi: 10.1016/j.cellsig.2009.02.012.

91. Davenport T.G., Jerome-Majewska L.A., Papaioannou V.E. Mammary gland, limb and yolk sac defects in mice lacking Tbx3, the gene mutated in human ulnar mammary syndrome. Development 2003; 130: 2263-2273.

92. Davicco M.J., Rouffet J., Durand D. Parathyroid hormone-related peptide my increase manimary blood fow. J Bone Min Res.1993; 8: 1519–1524.

93. Davis H., Raja E., Miyazono K., Tsubakihara Y., Moustakas A. Mechanisms of action of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev. 2016 Feb; 27: 81-92. doi: 10.1016/j.cytogfr.2015.11.009.

94. De Bakker C.M., Li Y., Zhao H., Leavitt L., Tseng W.J., Lin T., Tong W., Qin L., Liu X.S. Structural adaptations in the rat tibia bone induced by pregnancy and lactation confer protective effects against future estrogen deficiency. J Bone Miner Res. 2018; 33 (12): 2165–2176. doi: 10.1002/jbmr.3559.

95. Devys A., Lortholary A., Audran M. PTHrP and breast cancer. Bull. Cancer. 2001; 88: 1075-1080.

96. Diel I.J. Prognostic factors for skeletal relapse in breast cancer. Cancer Treat Rev. 2001 Jun; 27 (3): 153-7.

97. Dittmer A., Vetter M., Schunke D., Span P.N., Sweep F., Thomssen C., Dittmer J. Parathyroid hormone-related protein regulates tumor-relevant genes in breast cancer cells. J Biol Chem. 2006; 281 (21): 14563–14572. DOI: 10.1074/jbc.M510527200.

98. Dobnig H., Kainer F., Stepan V., Winter R., Lipp R., Schaffer M., Kahr A., Nocnik S., Patterer G., Leb G. Elevated parathyroid hormone-related peptide levels after human gestation: relationship to changes in bone and mineral metabolism. J Clin Endocrinol Metab. 1995; 80: 3699–3707.

99. Downey S.E., Hoyland J., Freemont A.J., Knox F., Walls J., Bundred N.J. Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue. J Pathol. 1997; 183: 212–217.

100. Du J., Yang S., Wang Z., Zhai C., Yuan W., Lei R., Zhang J. and Zhu T. Bone morphogenetic protein 6 inhibit stress-induced breast cancer cells apoptosis via both smad and P38 pathways. J. Cell. Biochem. 2008; 103: 1584-1597. doi: 10.1002/jcb.21547.

101. Duan X., Wang J., Jiang X. A meta-analysis of breastfeeding and osteoporotic fracture risk in the females. Osteoporos Int. 2017; 28 (2): 495–503. doi: 10.1007/s00198-016-3753-x.

102. Duivenvoorden W.C., Chattopadhyay N., Kifor O., Yamaguchi T., Butters R.R., Brown E.M. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology 2000; 141: 4357–64.

103. Duivenvoorden W.C., Hirte H.W., Singh G. Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 1999; 17: 27–34.

104. Dunbar M.E., Wysolmerski J.J. Parathyroid hormone-related protein: a developmental regulatory molecule necessary for mammary gland development. J. Mammary Gland Biol. Neoplasia. 1999; 4: 21–34.

105. Dunbar M.E., Dann P.R., Robinson G.W., Hennighausen L., Zhang J. P., Wysolmerski J.J. Parathyroid hormone-related protein signaling is necessary for sexual dimorphism during embryonic mammary development. Development. 1999; 126: 3485-3493.

106. Dunbar M.E., Young P., Zhang J.P., Mc Caughern C.J., Lanske B., Orloff J.J., Karaplis A.C., Cunha G., Wysolmerski J.J. Stromal ceils are critical targets in the regulation of mammary ductal morphogenesis by parathyroid hormone-related protein. Dey Biol. 1998; 203: 75–89.

107. Easton D.F., Pooley K.A., Dunning A.M., Pharoah P.D., Thompson D, Ballinger D.G. et al., Genome-wide association study identifies novel breast cancer susceptibility loci. Nature. 2007; 447 (7148): 1087–93.

108. Elston C.W., Ellis I.O.: Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410. 10.1111/j.1365-2559.1991.tb00229.x.

109. Fachal L., Aschard H., Beesley J., Barnes D.R., Allen J., Kar S., Pooley K.A., Dennis J., Michailidou K., Turman C., Soucy P., Lemacon A., Lush M., Tyrer J.P., Ghoussaini M. et l., Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nat Genet. 2020 Jan; 52 (1): 56-73. doi: 10.1038/s41588-019-0537–1.

110. Faddy H.M., Smart C.E., Xu R., Lee G.Y., Kenny P.A., Feng M., Rao R., Brown M.A., Bissell M.J., Roberts-Thomson S.J., Monteith G.R. Localization of plasma membrane and secretory calcium pumps in the mammary gland. Biochem Biophys Res Commun. 2008; 369: 977–981.

111. Falzon M., Du P. Enhanced growth of MCF-7 breast cancer cells overexpressing parathyroid hormone-related peptide. Endocrinology. 2000;
141: 1882–1892.

112. Fang J., Xu Q. Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics. Clin Transl Oncol. 2015 Mar; 17 (3): 173-9. doi: 10.1007/s12094-014-1247-x.

113. Feng Y., Spezia M., Huang S., Yuan C., Zeng Z., Zhang L., Ji X., Liu W., Huang B., Luo W, Liu B., Lei Y., Du S., Vuppalapati A., Luu H.H., Haydon R.C., He T.C., Ren G. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018 Jun; 5 (2): 77–106. doi: 10.1016/j.gendis.2018.05.001.

114. Ferguson J.E., Gorman J.V., Bruns D.E., Weir E.C., Burtis W.J., Martin T.J., Bruns M.E. Abundant expression of parathyroid hormone-related protein in human amnion and its association with labor. Proc Natl Acad Sci USA 1992; 89: 8384-8388.

115. Ferlay J., Soerjomataram I., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar 1; 136 (5):E359-86. doi: 10.1002/ijc.29210.

116. Ferrari S.L. Rizzoli R. Chaponnier C., Gabbiani G., Bonjour J.P. Parathyroid honnone-related protein increases cAMP production in mammary epithelial cells. Am J Physiol. 1993; E47: 1-5.

117. Fidler I.J. The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nat Rev Cancer. 2003; 3 (6): 453–458.

118. Figueroa J.D., Garcia-Closas M., Humphreys M., Platte R., Hopper J.L., Southey M.C. et al., Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. Human molecular genetics. 2011; 20 (23): 4693–706.

119. Fleming N.I., Trivett M.K., George J., Slavin J.L., Murray W.K., Moseley J.M., Anderson R.L., Thomas D.M. Parathyroid Hormone–Related Protein Protects against Mammary Tumor Emergence and Is Associated with Monocyte Infiltration in Ductal Carcinoma In situ. Cancer Res. 2009; 69 (18): 7473-7479. DOI: 10.1158/0008-5472.CAN-09-0194.

120. Fluck M.M., Schaffhausen B.S. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev. 2009; 73 (3): 542–563. doi: 10.1128/MMBR.00009-09.

121. Foley J., Dann P., Hong J., Cosgrove J., Dreyer B., Rimm D., Dunbar M., Philbrick W., Wysolmerski J. Parathyroid hormone-related protein maintains mammary epithelial fate and triggers nipple skin differentiation during embryonic breast development. Development. 2001; 128: 513–525.

122. Fox S., Lovibond A. Current insights into the role of transforming growth factor-beta in bone resorption. Mol Cell Endocrinol. 2005; 243: 19–26.

123. Friedman M.S., Oyserman S.M., Hankenson K.D. Wnt11 promotes osteoblast maturation and mineralization through R-spondin 2. J. Biol. Chem. 2009; 284: 14117–14125.

124. Fu Y.P., Edvardsen H., Kaushiva A., Arhancet J.P., Howe T.M., Kohaar I., Porter-Gill P., Shah A., Landmark-Hoyvik H., Fossa S.D., Ambs S., Naume B., Borresen-Dale A.L., Kristensen V.N., Prokunina-Olsson L. NOTCH2 in breast cancer: association of SNP rs11249433 with gene expression in ER-positive breast tumors without TP53 mutations. Molecular cancer. 2010; 9: 113. doi: 10.1186/1476-4598-9–113.

125. Gallwitz W.E., Guise T.A., Mundy G.R. Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest. 2002; 110: 1559–72.

126. Ganapathy V., Ge R., Grazioli A., Xie W., Banach-Petrosky W., Kang Y., Lonning S., McPherson J., Yingling J.M., Biswas S., Mundy G.R., Reiss M. Targeting the transforming growth factor-b pathway inhibits human basallike breast cancer metastasis. Mol Cancer. 2010; 9: 122–37.

127. Garcia-Closas M., Couch F.J., Lindstrom S., Michailidou K., Schmidt M.K., Brook M.N. et al., Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013; 45 (4):
392–8. 98e1–2.

128. Ghoussaini M., Fletcher O., Michailidou K., Turnbull C., Schmidt M.K., Dicks E., Dennis J., Wang Q., Humphreys M.K., Luccarini C., Baynes C., Conroy D., Maranian M., Ahmed S., Driver K., Johnson N., Orr N., Dos Santos Silva I., Waisfisz Q., Meijers-Heijboer H., Uitterlinden A.G., Rivadeneira F. Netherlands Collaborative Group on Hereditary Breast and Ovarian Cancer (HEBON) et al. Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet. 2012; 44 (3): 312–318. doi: 10.1038/ng.1049.

129. Giancotti F.G. Mechanisms governing metastatic dormancy and reactivation. Cell. 2013; 155 (4): 750–64. doi: 10.1016/j.cell.2013.10.029.

130. Gilkes D.M. Implications of hypoxia in breast cancer metastasis to bone. Int. J. Mol. Sci. 2016; 17: E1669. doi: 10.3390/ijms17101669.

131. Gillespie M.T. and Martin, T.J. The parathyroid hormone-related protein gene and its expression. Mol. Cell Endocrinol. 1994; 100: 143–147.

132. Gillies B.R., Ryan B.A., Tonkin B.A., Poulton I.J., Ma Y., Kirby B.J., St-Arnaud R., Sims N.A., Kovacs C.S. Absence of calcitriol causes increased lactational bone loss and lower milk calcium but does not impair post-lactation bone recovery in Cyp27b1 null mice. J Bone Miner Res. 2018; 33 (1): 16–26.

133. Goff J.P. Calcium and magnesium disorders. Vet. Clin. North Am.: Food Anim. Pract. 2014; 30 (2): 359–381. doi: 10.1016/j.cvfa.2014.04.003.

134. Goltzman D., Hendy G.N. The calcium-sensing receptor in bone–mechanistic and therapeutic insights. Nature Reviews. Endocrinology. 2015; 11 (5): 298–307. doi: 10.1038/nrendo.2015.30.

135. Gonzalez-Suarez E., Jacob A.P., Jones J. et al., RANK ligand mediates progestininduced mammary epithelial proliferation and carcino-genesis. Nature. 2010; 468: 103–107.

136. Gregory L.S., Choi W., Burke L., Clements J.A. Breast cancer cells induce osteolytic bone lesions in vivo through a reduction in osteoblast activity in mice. PLoS One. 2013; 8 (9, article e68103) doi: 10.1371/journal.pone.0068103.

137. Grill V., Hillary J., Ho P.M.W., Law F.M., MacIsaac R.J., MacIsaac I.A., Moseley J.M., Martin T.J. Parathyroid hormone-related protein: a possible endocrine function in lactation. Clin Endocrinol (Oxf) 1992; 37: 405-410.

138. Gudlur A., Hogan P.G. The STIM-Orai Pathway: Orai, the Pore-Forming Subunit of the CRAC Channel. Adv Exp Med Biol. 2017; 993: 39-57. doi: 10.1007/978-3–319-57732-6_3.

139. Guise T.A., Chirgwin J.M. Transforming growth factor-beta in osteolytic breast cancer bone metastases. Clinical Orthopaedics and Related Research. 2003; 415:S32–S38. doi: 10.1097/01.blo.0000093055.96273.69.

140. Guise T.A., Yin J.J., Taylor S.D., Kumagai Y., Dallas M., Boyce B.F., Yoneda T., Mundy G.R. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest. 1996; 98: 1544–1549.

141. Guise T.A., Mundy G.R. Cancer and bone. Endocr Rev. 1998; 19: 18–54.

142. Guise T.A., Yin J.J., Thomas R.J., Dallas M., Cui Y., Gillespie M.T. Parathyroid hormone-related protein (PTHrP)-(1–139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Bone 2002; 30: 670–676.

143. Guisse T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., Vessella R., Corey E., Padalecki S., Suva L., Chirgwin J.M. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res. 2006; 12 (20 Pt 2): 6213s-6216s.

144. Hadjidakis D.J., Androulakis I.I. Bone remodeling. Ann. N.Y. Acad. Sci. 2006; 1092: 385–96. doi: 10.1196/annals.1365.035.

145. Hanavadi S., Martin T.A., Watkins G. Mansel R.E., Jiang W.G. The Role of Growth Differentiation Factor-9 (GDF-9) and Its Analog, GDF-9b/BMP-15, in Human Breast Cancer. Ann Surg Oncol. 2007; 14: 2159–2166. doi: 10.1245/s10434-007-9397-5.

146. Hangen E., Blomgren K., Benit P., Kroemer G., Modjtahedi N. Life with or without AIF. Trends in biochemical sciences. 2010; 35: 278–87.

147. Hartkopf A.D., Stefanescu D., Wallwiener M. Tumor cell dissemination to the bone marrow and blood is associated with poor outcome in patients with metastatic breast cancer. Breast Cancer Res Treat. 2014; 147 (2): 345–351.

148. Hartmann P.E., Sherriff J.L., Mitoulas L.R. Homeostatic mechanisms that regulate lactation during energetic stress. J. Nutr. 1998; 128 (2. Suppl): 394S–399S.

149. Hatse S., Princen K., Bridger G., De Clercq E., Schols D. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett. 2002; 527 (1–3): 255–262. doi: 10.1016/S0014-5793 (02) 03143–5.

150. Hatsell S.J., Cowin P. Gli3-mediated repression of Hedgehog targets is required for normal mammary development. Development. 2006; 133:

151. He B., Deckelbaum R.A., Miao D., Lipman M.L., Pollak M., Goltzman D., Karaplis A.C. Tissue-specific targeting of the pthrp gene: the generation of mice with floxed alleles. Endocrinology. 2001; 142: 2070-2077.

152. Henderson M.A., Danks J.A., Moseley J.M., Slavin J., Harris T., McKinlay M., Hopper J.L., Martin T.J. Parathyroid hormone-related protein production by breast cancers associated with improved survival, and reduced bone metastases. J Natl Cancer Inst 2001; 93: 234–237.

153. Henderson M.A., Danks J.A., Slavin J.L., Byrnes G.B., Choong P.F., Spillane J.B., Hopper J.L., Martin T.J. 2006. Parathyroid hormone-related protein localization in breast cancers predict improved prognosis. Cancer Res., 66: 2250-2256. doi: 10.1158/0008-5472.CAN-05-2814.

154. Hennessy B.T., Smith D.L., Ram P.T., Lu Y., Mills G.B. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov. 2005; 4 (12): 988–1004.

155. Hens J., Dann P., Hiremath M., Pan T.C., Chodosh L., Wysolmerski J. (2009) Analysis of gene expression in PTHrP?/? mammary buds supports
a role for BMP signaling and MMP2 in the initiation of ductal morphogenesis. Developmental Dynamics. 2009; 238 (11): 2713–2724.

156. Hens J.R., Dann P., Zhang J.P., Harris S., Robinson G.W., Wysolmerski J. (2007). BMP4 and PTHrP interact to stimulate ductal outgrowth during embryonic mammary development and to inhibit hair follicle induction. Development. 2007; 134 (6): 1221–1230.

157. Hens J.R., Wysolmerski J.J. Key stages of mammary gland development: Molecular mechanisms involved in the formation of the embryonic mammary gland. Breast Cancer Research. 2005; 7 (5): 220–224.

158. Hernandez L.L., Limesand S.W., Collier J.L., Horseman N.D., Collier R.J. The bovine mammary gland expressed multiple functional isoforms of serotonin receptors. J. Endocrinol. 2009; 203: 123–131. doi: 10.1677/JOE-09-0187.

159. Hernandez L.L., Gregerson K.A., Horseman N.D. Mammary gland serotonin regulates parathyroid hormone-related protein and other
bone-related signals. Am J Physiol Endocrinol Metab. 2012; 302 (8): E1009–E1015. doi: 10.1152/ajpendo.00666.2011.

160. Hernandez L.L. TRIENNIAL LACTATION SYMPOSIUM/BOLFA: Serotonin and the regulation of calcium transport in dairy cows. J Anim Sci. 2017 Dec; 95 (12): 5711-5719. doi: 10.2527/jas2017.1673.

161. Hillman L.S., Forte L.R., Veum T., Ru Y., Howard B., Rowe A., Hillman H.W. Effect of parathyroid hormone-related peptide supplementation of soy protein formulas in the neonatal pig model. J. Bone Miner. Res. 1994; 9: 1047–1052.

162. Hiraki A., Ueoka H., Bessho A., Segawa Y., Takigawa N., Kiura K., Eguchi K., Yoneda T., Tanimoto M., Harada M. Parathyroid hormone-related protein measured at the time of first visit is an indicator of bone metastases and survival in lung carcinoma patients with hypercalcemia. Cancer. 2002; 95 (8): 1706–1713. doi: 10.1002/cncr.10828.

163. Hiremath M., Dann P., Fischer J., Butterworth D., Boras-Granic K., Hens J., Van Houten J., Shi W., Wysolmerski J. Parathyroid hormone-related protein activates Wnt signaling to specify the embryonic mammary mesenchyme. Development. 2012; 139: 4239-4249. doi: 10.1242/dev.080671.

164. Hiremath M., Wysolmerski J. Role of PTHrP in mammary gland development and breast cancer. Clin. Rev. Bone Miner. Metab. 2014; 12: 178–189. doi: 10.1007/s12018-014-9170-9.

165. Hiremath M., Wysolmerski J. Parathyroid Hormone-Related Protein Specifies the Mammary Mesenchyme and Regulates Embryonic Mammary Development. J Mammary Gland Biol Neoplasia. 2013 Jun; 18 (2): 171–177. doi: 10.1007/s10911-013-9283-7.

166. Hoey R.P., Sanderson C., Iddon J., Brady G., Bundred N.J., Anderson N.G. The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br. J. Cancer. 2003; 88: 567-573.

167. Horne H.N., Chung C.C., Zhang H., Yu K., Prokunina-Olsson L., Michailidou K. et al., Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE. 2016; 11 (8):e0160316. doi.org/10.1371/journal.pone.0160316

168. Horseman N.D., Hernandez L.L. New concepts of breast cell communication to bone. Trends Endocrinol. Metab. 2014; 25: 34–41.

169. Horst R.L., Goff J.P., Reinhardt T.A. Calcium and vitamin D metabolism during lactation. J. Mammary Gland Biol. Neoplasia. 1997; 2: 253-263.

170. Hosseini H., Obradovic M.M., Hoffmann M. Early dissemination seeds metastasis in breast cancer. Nature. 2016; 540 (7634): 552.

171. Huebner R.J., Ewald A.J. Cellular foundations of mammary tubulogenesis. Semin Cell Dev Biol. 2014; 31: 124–131.

172. Hunter T. Signaling–2000 and beyond. Cell. 2000; 100 (1): 113–127.

173. Hunter T. The age of crosstalk: phosphorylation, ubiquitination, and beyond. Mol Cell. 2007; 28 (5): 730–738.

174. Hwang I.R., Choi Y.K., Lee W.K., Kim J.G., Lee I.K., Kim S.W., Park K.G. Association between prolonged breastfeeding and bone mineral density and osteoporosis in postmenopausal women: KNHANES 2010-2011. Osteoporos Int. 2016; 27 (1): 257–265. doi: 10.1007/s00198-015-3292-x.

175. Ibaragi S., Shimo T., Iwamoto M. Parathyroid hormone-related peptide regulates matrix metalloproteinase-13 gene expression in bone metastatic breast cancer cells. Anticancer Res/ 2010; 30 (12): 5029–36.

176. Iezzoni J.C., Bruns M.E., Frierson H.F., Scott M.G., Pence R.A., Deftos L.J., Bruns D.E. Coexpression of parathyroid hormone-related protein arid its receptor in breast carcinoma: a potential autocrine effector system. Mod Pathol. 1998; 11: 265-270.

177. Ikeda K., Mangin M., Dreyer B.E., Webb A.C., Posillico J.T., Stewart, A.F., Bander N.H.b, Weir E.C., Insogna K.L., Broadus A.E. Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. J Clin Invest. 1988; 81: 2010-2014.

178. Isowa S., Shimo T., Ibaragi S., Kurio N., Okui T., Matsubara K., Hassan N.M., Kishimoto K., Sasaki A. PTHrP regulates angiogenesis and bone resorption via VEGF expression. Anticancer Res 2010; 30 (7): 2755–67.

179. Jahn K., Kelkar S., Zhao H., Xie Y., Tiede-Lewis L.M., Dusevich V., Dallas S.L., Bonewald L.F. Osteocytes Acidify Their Microenvironment in Response to PTHrP In Vitro and in Lactating Mice In Vivo. J Bone Miner Res. 2017 Aug; 32 (8): 1761–1772. doi: 10.1002/jbmr.3167.

180. Jemtland R., Diveiti P., Lee K., Segre G.V. Hedgehog promotes primary osteoblast differentiation and increases PTHrP mRNA expression and iPTHrP secretion. Bone. 2003; 32: 611–620. doi: 10.1016/S8756-3282 (03) 00092-9.

181. Jiang Z., Jones R., Liu J.C., Deng T., Robinson T., Chung P.E., Wang S., Herschkowitz J.I., Egan S.E., Perou C.M., Zacksenhaus E. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. 2011; 10: 1563–1570. doi: 10.4161/cc.10.10.15703.

182. John E.M., Hines L.M., Phipps A.I., Koo J., Longacre T.A., Ingles S.A., Baumgartner K.B., Slattery M.L., Wu A.H. Reproductive history, breast-feeding and risk of triple negative breast cancer: the breast Cancer etiology in minorities (BEM) study. Int J Cancer. 2018; 142 (11): 2273–2285. doi: 10.1002/ijc.31258.

183. Johnson R.W., Finger E.C., Olcina M.M., Vilalta M., Aguilera T., Miao Y., Merkel A.R., Johnson J.R., Sterling J.A., Wu J.Y., Giaccia A.J. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol. 2016; 18 (10): 1078–89. doi: 10.1038/ncb3408.

184. Johnson R.W., Sun Y., Ho P.W.M., Chan A.S.M., Johnson J.A., Pavlos N.J., Sims N.A., Martin T.J. Parathyroid Hormone-Related Protein Negatively Regulates Tumor Cell Dormancy Genes in a PTHR1/Cyclic AMP-Independent Manner. Front. Endocrinol. 2018; 9: 241. doi: 10.3389/fendo.2018.00241.

185. Jun A.Y., Kim H., Park K., Son K.H., Lee D.H., Woo M., Chung W. Tetrahydrofurofuran-type lignans inhibit breast cancer-mediated bone destruction by blocking the vicious cycle between cancer cells, osteoblasts and osteoclasts. Invest New Drugs. 2014; 32: 1–13. doi: 10.1007/s10637-013-9969-0.

186. Juppner H., Abou-Samra A.B., Freeman M., Kong X.F., Schipani E., Richards J., Kolakowski L.F.Jr., Hock J., Potts J.T.Jr., Kronenberg H.M., Segre G.V. AG protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science. 1991; 254: 1024-1026.

187. Kalkwarf H.J., Specker B.L., Bianchi D.C., Ranz J., Ho M. The effect of calcium supplementation on bone density during lactation and after weaning. N Engl J Med. 1997; 337 (8): 523–528.

188. Kalkwarf H.J. Effects of Calcium Supplementation on Calcium Homeostasis and Bone Turnover in Lactating Women. J Clin Endocrinol Metab. 1999; 84: 464–470. 10.1210/jcem.84.2.5451.

189. Kamalakar A., Washam C.L., Akel N.S., Allen B.J., Williams D.K., Swain F.L., Leitzel K., Lipton A., Gaddy D., Suva L.J. PTHrP (12–48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan. J Bone Miner Res. 2017; 32 (7): 1421–1431. doi: 10.1002/jbmr.3142.

190. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., Guise T.A., Massague J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 2003; 3: 537–549. doi: 10.1016/S1535-6108 (03) 00132-6.

191. Kantham L., Quinn S.J., Egbuna O.I., Baxi K., Butters R., Pang J.L., Pollak M.R., Goltzman D., Brownet E.M. The calcium-sensing receptor (CaSR) defends against hypercalcemia independently of its regulation of parathyroid hormone secretion. Am J Physiol Endocrinol Metab. 2009; 297 (4):E915–E923.

192. Karami F., Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013; 2013: 928562. DOI: 10.1155/2013/928562.

193. Katoh Y., Katoh M. Hedgehog signaling pathway and gastric cancer. Cancer Biol Ther. 2005; 4: 1050–1054.

194. Katoh Y., Katoh M. Hedgehog target genes: Mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009; 9: 873–886. doi: 10.2174/156652409789105570.

195. Kaya A.E., Dogan O., Basbug A., Sonmez C.I., Sungur M.A., Ataoglu S. An evaluation of the Association of Reproductive History and Multiple Births during adolescence with postmenopausal osteoporosis. Geburtshilfe Frauenheilkd. 2019; 79 (3): 300–307. doi: 10.1055/a-0743-7260.

196. Khosla S., Johanson K.L., Ory S.J. Parathyroid hormone-related peptide in lactation and umbilical cord blood. Myo Clin Proc. 1990a; 65: 1408-1412.

197. Khosla S., Van Heerden J.A., Gharib H., Jackson I.T., Danks J., Hayman J.A., Martin T.J. Parathyroid hormone-related protein and hypercalcemia secondary to massive mammary hyperplasia. New England Journal of Medicine. 1990b; 322 (16), 1157.

198. Khramtsov A.I., Khramtsova G.F., Tretiakova M., Huo D., Olopade O.I., Goss K.H. Wnt/beta-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome. Am J Pathol. 2010; 176 (6): 2911–2920.

199. Kim H.J., Kwon H., Oh S.W., Lee C.M., Joh H.K., Kim Y., Um Y.J., Ahn S.H. Breast feeding is associated with postmenopausal bone loss: findings from the Korea National Health and nutrition examination survey. Korean J Fam Med. 2015; 36 (5): 216–220. doi: 10.4082/kjfm.2015.36.5.216.

200. Kim K.A., Wagle M., Tran K., Zhan X., Dixon M.A., Liu S., Gros D., Korver W., Yonkovich S., Tomasevic N., Binnerts M., Abo A. R-Spondin family members regulate the Wnt pathway by a common mechanism. Mol. Biol. Cell. 2008; 19: 2588-2596.

201. Kim W., Takyar F.M., Swan K., Jeong J., VanHouten J., Sullivan C., Dann P., Yu H., Fiaschi-Taesch N., Chang W., John Wysolmerskiet J. Calcium-sensing receptor promotes breast cancer by stimulating intracrine actions of parathyroid hormone-related protein. Cancer Res. 2016; 76 (18): 5348–60. doi: 10.1158/0008-5472.CAN-15-2614.

202. Kim W., Wysolmerski J.J. Calcium-sensing receptor in breast physiology and cancer. Frontiers in Physiology. 2016; 7 doi: 10.3389/fphys.2016.00440.

203. Kingsley L., Fournier P., Chirgwin J. Molecular biology of bone metastasis. Mol Cancer Ther 2007; 6: 2609–17.

204. Kiriyama T., Gillespie M.T., Glatz J.A., Fukumoto S., Moseley J.M., Martin T.J. Transforming growth factor b stimulation of parathyroid hormone–related protein (PTHrP): a paracrine regulator? Mol Cell Endocrinol. 1992; 92: 55–62.

205. Kissin M.W., Henderson M.A., Danks J.A., Hayman J.A., Bennett R.C., Martin T.J. Parathyroid hormone related protein in breast cancers of widely varying prognosis. Eur J Surg Oncol. 1993 Apr; 19 (2): 134-42.

206. Klein C.A. Cancer. The metastasis cascade. Science. 2008; 321 (5897): 1785–1787.

207. Klein C.A. Parallel progression of primary tumours and metastases. Nat Rev Cancer. 2009; 9 (4): 302–312.

208. Kocabagli N., Riond J.L., Spichiger U.E. Wanner M. Parathyroid hormone-related protein and calcium homeostasis during the periparturient period of dairy cows. Am. J. Vet. Res.1995; 56: 380-385.

209. Kohno N., Kitazawa S., Fukase M., Sakoda Y., Kanbara Y., Furuya Y., Ohashi O., Ishikawa Y., Saitoh Y. The expression of parathyroid hormone-related protein in human breast cancer with skeletal metastases. Surg Today 1994a; 24: 215–20.

210. Kohno N., Kitazawa S., Sakoda Y., Kanbara Y., Furuya Y., Ohashi O., Kitazawa R. Parathyroid hormone-related protein in breast cancer tissues: relationship between primary and metastatic sites. Breast Cancer. 1994b; 1: 43–49.

211. Kolker E., Higdon R., Haynes W., Welch D., Broomall W., Lancet D., Stanberry L., Kolker N. MOPED: Model Organism Protein Expression Database. Nucleic Acids Res. 2012; 40 (Database issue): D1093–9. doi: 10.1093/nar/gkr1177.

212. Kominsky S., Davidson N.A. ‘‘Bone’’ fide predictor of metastasis? Predicting breast cancer metastasis to bone. JCO 2006; 24 (15): 2227–9.

213. Komori T. Regulation of bone development and maintenance by Runx2. Front Biosci. 2008; 13: 898–903.

214. Kovacs C.S., Chik C.L. Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH-related peptide levels. J Clin Endocrinol Metab. 1995: 80: 3036–3042.

215. Kovacs C.S. Calcium and bone metabolism during pregnancy and lactation. J Mammary Gland Biol Neoplasia. 2005; 10: 105–118.

216. Kovacs C.S. Calcium and bone metabolism in pregnancy and lactation. J Clin Endocrinol Metab. 2001; 86: 2344–2348.

217. Kovacs C.S. Maternal Mineral and Bone Metabolism During Pregnancy, Lactation, and Post-Weaning Recovery. Physiol Rev. 2016 Apr; 96 (2): 449-547. doi: 10.1152/physrev.00027.2015.

218. Kovacs C.S. The Role of PTHrP in Regulating Mineral Metabolism During Pregnancy, Lactation, and Fetal/Neonatal Development Clinic Rev Bone Miner Metab. 2014; 12 (3): 142–164. doi: 10.1007/s12018-014-9157-6.

219. Kovacs C.S., Kronenberg H.M. Maternal-fetal calcium and bone metabolism during pregnancy, puerperium, and lactation. Endocr. Rev. 1997; 18: 832-872.

220. Kozlow W. and Guise T.A. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10: 169–180.

221. Kremer R., Li J., Camirand A., Karaplis A.C. Parathyroid hormone related protein (PTHrP) in tumor progression. Adv Exp Med Biol. 2011; 720: 145-60. doi: 10.1007/978-1-4614-0254-1_12.

222. Kuchenbaecker K.B., Neuhausen S.L., Robson M., Barrowdale D., McGuffog L., Mulligan A.M. et al., Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 2014; 16 (6): 3416. doi: 10.1186/s13058-014-0492-9.

223. Kumaran M., Ghosh S., Joy A.A., Mackey J.R., Cass C.E., Zheng W., Yasui Y., Damaraju S Fine-mapping of a novel premenopausal breast cancer susceptibility locus at Chr4q31.22 in Caucasian women and validation in African and Chinese women. Int J Cancer. 2020 Mar 1; 146 (5): 1219–1229. doi: 10.1002/ijc.32407.

224. Laporta J., Keil K.P., Vezina C.M., Hernandez L.L. Peripheral serotonin regulates maternal calcium trafficking in mammary epithelial cells
during lactation in mice. PLoS One. 2014a; 9 (10):e110190. doi: 10.1371/journal.pone.0110190.

225. Laporta J., Keil K.P., Weaver S.R., Cronick C.M., Prichard A.P., Crenshaw T.D., Heyne G.W., Vezina C.M., Lipinski R.J., Hernandez L.L. Serotonin regulates calcium homeostasis in lactation by epigenetic activation of hedgehog signaling. Mol. Endocrinol. 2014b; 28 (11): 1866–1874. doi: 10.1210/me.2014-1204.

226. Lee E.N., Choe S.Y., Choi E.H., Lee M.J. Effects of Parity and Breast Feeding Duration on the Risk of Osteoporosis in Postmenopausal Korean Women: A Systematic Review and Meta-Analysis. J Menopausal Med. 2019 Aug; 25 (2): 100-107. doi: 10.6118/jmm.19197.

227. Lenora J., Lekamwasam S., Karlsson M.K. Effects of multiparity and prolonged breast-feeding on maternal bone mineral density: a community-based cross-sectional study.BMC Womens Health. 2009; 9: 19. doi: 10.1186/1472-6874-9–19.

228. Lepre F., Grill V., Ho P.W., Martin T.J. Hypercalcemia in pregnancy and lactation associated with parathyroid hormone-related protein. N Engl J Med. 1993; 328 (9): 666-667.

229. Li B.T., Wong M.H., Pavlakis N. Treatment and Prevention of Bone Metastases from Breast Cancer: A Comprehensive Review of Evidence for Clinical Practice. J. Clin. Med. 2014, 3 (1), 1–24; doi.org/10.3390/jcm3010001.

230. Li H., Sun Y., Zheng H., Li L., Yu Q., Yao X. Parathyroid hormone-related protein overexpression protects goat mammary gland epithelial cells from calcium-sensing receptor activation-induced apoptosis. Molecular biology reports. 2015; 42: 233–43.

231. Li J., Karaplis A.C., Huang D.C., Siegel P.M., Camirand A., Yang X.F., Muller W.J., Kremer R. PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest. 2011; 121 (12): 4655–4669. doi: 10.1172/JCI46134.

232. Li J., Zhang Z., Rosenzweig J., Wang Y.Y., Chan D.W. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem. 2002; 48 (8): 1296–1304.

233. Li S., Peng Y., Weinhandl E.D., Blaes A.H., Cetin K., Chia V.M., Stryker S., Pinzone J.J., Acquavella J.F., Arneson T.J. Estimated number of prevalent cases of metastatic bone disease in the US adult population. Clin Epidemiol. 2012; 4: 87-93.

234. Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., Zhou X., Xia W., Hortobagyi G.N., Yu D., Hung M.C. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004; 6 (5): 459–469. doi: 10.1016/j.ccr.2004.09.027.

235. Li Z., Kang Y. Emerging therapeutic targets in metastatic progression: a focus on breast cancer. Pharmacol Ther. 2016; 161: 79-96.

236. Liang Z., Yoon Y., Votaw J., Goodman M.M., Williams L., Shim H. Silencing of CXCR4 blocks breast cancer metastasis. Cancer Res. 2005; 65 (3): 967–971.

237. Liapis H., Crouch E.C., Grosso L.E., Kitazawa S., Wick M.R. Expression of parathyroidlike protein in normal, proliferative, and neoplastic human breast tissues. Am J Pathol. 1993; 143: 1169–1178.

238. Lim E., Wu D., Pal B., Bouras T., Asselin-Labat M.L., Vaillant F., Yagita H., Lindeman G.J., Smyth G.K., Visvader J.E. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010; 12:R21. doi: 10.1186/bcr2560.

239. Lin S.Y., Xia W., Wang J.C. Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin D1 expression and cancer progression. Proc Natl Acad Sci USA. 2000; 97 (8): 4262–4266.

240. Lindemann R.K. Ballschmieter P., Nordheim A., Dittmer J. Transforming growth factor beta regulates parathyroid hormone-related protein expression in MDA-MB231 breast cancer cells through a novel Smad/Ets synergism. J Biol Chem. 2001; 276: 46661–46670.

241. Linforth R., Anderson N., Hoey R., Nolan T., Downey S., Brady G., Ashcroft L., Bundred, N. Coexpression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clin Cancer Res. 2002; 8: 3172-3177.

242. Lippuner K., Zehnder H.J., Casez J.P., Takkinen R., Jaeger P. PTH-related protein is released into the mother’s bloodstream during location: evidence for beneficial effects on maternal calcium-phosphate metabolism. J. Bone Miner. Res. 1996; 11: 1394-1399.

243. Lipton A., Steger G.G., Figueroa J., Alvarado C., Solal-Celigny P., Body J.J., de Boer R., Berardi R., Gascon P., Tonkin K.S., Coleman R., Paterson A.H., Peterson M.C., Fan M., Kinsey A., Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol. 2007; 25 (28): 4431-7.

244. Lipton A. Biochemical bone markers in breast cancer. Cancer Treat Rev 2006; 32 (Suppl 1): 20–2.

245. Liu N.Q., Braakman R.B., Stingl C., Luider T.M., Martens J.W., Foekens J.A., Umar A. Proteomics pipeline for biomarker discovery of laser capture microdissected breast cancer tissue. J Mammary Gland Biol Neoplasia. 2012; 17: 155–64.

246. Loibl S., Konigs A., Kaufmann M., Costa S.D., Bischoff J. PTHrP and bone sialoprotein as prognostic markers for developing bone metastases in breast cancer patients. Zentralbl Gynakol. 2006 Dec; 128 (6): 330-5.

247. Lotinun S., Ishihara Y., Nagano K., Kiviranta R., Carpentier VT., Neff L., Parkman V., Ide N., Hu D., Dann P4, Brooks D., Bouxsein ML., Wysolmerski J., Gori F., Baron R. Cathepsin K-deficient osteocytes prevent lactation-induced bone loss and parathyroid hormone suppression. J Clin Invest. 2019 May 21; 129: 3058-3071. doi: 10.1172/JCI122936.

248. Loupy A., Ramakrishnan S.K., Wootla B., Chambrey R., de la Faille R., Bourgeois S., Bruneval P., Mandet C., Christensen E.I., Faure H., Cheval L., Laghmani K., Collet C., Eladari D., Dodd R.H., Ruat M., Houillier P. PTH-independent regulation of blood calcium concentration by the calcium-sensing receptor. J Clin Invest. 2012; 122 (9): 3355–3367.

249. Lu X., Mu E., Wei Y., Riethdorf S., Yang Q., Yuan M., Yan J., Hua Y., Tiede B.J., Lu X., Haffty B.G., Pantel K., Massague J., Kang Y. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging ?4?1-positive osteoclast progenitors. Cancer Cell. 2011; 20: 701–714. doi: 10.1016/j.ccr.2011.11.002.

250. Lubetzky R., Weisman Y., Dollberg S., Herman L., Mandel D. Parathyroid hormone-related protein in preterm human milk. Breastfeed Med. 2010 Apr; 5 (2): 67-9. doi: 10.1089/bfm.2008.0142.

251. Luker K.E., Luker G.D. Functions of CXCL12 and CXCR4 in breast cancer. Cancer Lett. 2006; 238 (1): 30–41. doi: 10.1016/j.canlet.2005.06.021.

252. Luparello C., Sirchia R., Lo Sasso B. Midregion PTHrP regulates Rip1 and caspase expression in MDA-MB231 breast cancer cells. Breast Cancer Res Treat. 2008; 111: 461–474. doi: 10.1007/s10549-007-9816-0.

253. Luparello C. Midregion PTHrP and human breast cancer cells. ScientificWorldJournal. 2010; 10: 1016–1028. doi: 10.1100/tsw.2010.97.

254. Luparello C., Birch M.A., Gallagher J.A., Burtis W.J. Clonal heterogeneity of the growth and invasive response of a human breast carcinoma cell line to parathyroid hormone-related peptide fragments. Carcinogenesis. 1997; 18: 23–29.

255. Luparello C., Burtis W.J., Raue F., Birch M.A., Gallagher J.A. Parathyroid hormone-related peptide and 8701-BC breast cancer cell growth and invasion in vitro: evidence for growth-inhibiting and invasion-promoting effects. Mol. Cell. Endocrinol. 1995; 111: 225-232.

256. Luparello C., Romanotto R., Tipa A., Sirchia R., Olmo N., Lopez de Silanes I., Turnay J., Lizarbe M.A., Stewart A.F. Midregion parathyroid hormone-related protein inhibits growth and invasion in vitro and tumorigenesis in vivo of human breast cancer cells. J. Bone Miner. Res. 2001; 16: 2173–2181.

257. Luparello C., Sirchia R., Pupello D. PTHrP [67–86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression. J. Cell Sci. 2003; 116: 2421–2430.

258. Luparello C., Librizzi M., Asaro D.M., Cruciata I., Caradonna F. Mid-region parathyroid hormone-related protein is a genome-wide chromatin-binding factor that promotes growth and differentiation of HB2 epithelial cells from the human breast. BioFactors. 2019; 45: 279-288. doi: 10.1002/biof.1484.

259. Macias H., Hinck L. Mammary gland development. Wiley Interdiscip Rev Dev Biol. 2012; 1 (4): 533–557.

260. Malkas L.H., Herbert B.S., Abdel-Aziz W., Dobrolecki L.E., Liu Y., Agarwal B., Hoelz D., Badve S., Schnaper L., Arnold R.J., Mechref Y., Novotny M.V., Loehrer P., Goulet R.J., Hickey R.J. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proc Natl Acad Sci U S A. 2006; 103 (51): 19472–19477. doi: 10.1073/pnas.0604614103.

261. Mamillapalli R., VanHouten J., Dann P., Bikle D., Chang W., Brown E., Wysolmerski J. Mammary-specific ablation of the calcium-sensing receptor during lactation alters maternal calcium metabolism, milk calcium transport, and neonatal calcium accrual. Endocrinology. 2013 Sep; 154 (9): 3031-42. doi: 10.1210/en.2012-2195.

262. Mamillapalli R., VanHouten J., Zawalich W., Wysolmerski J. Switching of G-protein usage by the calcium-sensing receptor reverses its effect on parathyroid hormone-related protein secretion in normal versus malignant breast cells. J Biol Chem. 2008; 283: 24435–47.

263. Manders K., van de Poll-Franse L.V., Creemers G.J., Vreugdenhil G., van der Sangen M.J., Nieuwenhuijzen G.A., Roumen R.M., Voogd A.C. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer. 2006; 6: 179. doi: 10.1186/1471–2407-6-179.

264. Mardones G.A., Burgos P.V., Brooks D.A., Parkinson-Lawrence E., Mattera R., Bonifacino J.S. The trans-Golgi network accessory protein p56 promotes long-range movement of GGA/clathrin-containing transport carriers and lysosomal enzyme sorting. Mol Biol Cell. 2007; 18 (9): 3486–501. doi: 10.1091/mbc.E07-02-0190.

265. Marshall A.M., Nommsen-Rivers L.A., Hernandez L.L., Dewey K.G., Chantry C.J., Gregerson K.A., Horseman N.D. Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution. J. Clin. Endocrinol. Metab. 2010; 95: 837–846.

266. Martin T.J. Manipulating the environment for cancer cells in bone; a novel therapeutic approach. J Clin Invest 2002; 110: 1399–401.

267. Martin T.J. Moseley, J.M. and Williams, E.D. Parathyroid hormone-related protein:hormone and cytokine. J Endocrinol. 1997; 154:S23-S37.

268. Martin T.J, Johnson R.W. Multiple actions of parathyroid hormone-related protein in breast cancer bone metastasis. Br J Pharmacol. 2019; 1– 13. https://doi.org/10.1111/bph.14709.

269. Matsuda M.T., Imaoka A.J., Vomachka G.A., Gudelsky Z.Y., Hou M., Mistry J.P., Bailey K.M., Nieport D.J., Walther M., Bader, Horseman N.D. Serotonin regulates mammary gland development via an autocrine-paracrine loop. Developmental cell. 2004; 6: 193–203.

270. Matsuo K., Irie N. Osteoclast-osteoblast communication. Arch. Biochem. Biophys. 2008; 473 (2): 201–209. doi: 10.1016/j.abb.2008.03.027.

271. McGuire A., Brown J.A., Kerin M.J. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastas-. Rev. 2015; 34: 145–155. doi: 10.1007/s10555-015-9551-7.

272. Meding S., Nitsche U., Balluff B., Elsner M., Rauser S., Schone C., Nipp M., Maak M., Feith M., Ebert M.P., Friess H., Langer R., Hofler H., Zitzelsberger H., Rosenberg R., Walch A. Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. J Proteome Res. 2012; 11 (3): 1996–2003.

273. Melle C., Ernst G., Schimmel B., Bleul A., Koscielny S., Wiesner A., Bogumil R., Moller U., Osterloh D., Halbhuber K.J., von Eggeling A. technical triade for proteomic identification and characterization of cancer biomarkers. Cancer Res 2004; 64 (12): 4099–4104.

274. Michailidou K., Hall P., Gonzalez-Neira A., Ghoussaini M., Dennis J., Milne R.L., et al., Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet. 2013; 45 (4): 353–61. 61e1–2.

275. Mihai R., Stevens J., McKinney C., Ibrahim N.B. Expression of the calcium receptor in human breast cancer--a potential new marker predicting the risk of bone metastases. Eur J Surg Oncol. 2006; 32: 511–5.

276. Mihai R. The calcium sensing receptor: from understanding parathyroid calcium homeostasis to bone metastases. Ann R Coll Surg Engl 2008; 90 (4): 271–7.

277. Minafra S., Morello V., Glorioso F., La Fiura A.M., Tomasino R.M., Feo S., McIntosh D., Woolley D.E. A new cell line (8701-BC) from primary ductal infiltrating carcinoma of human breast. Br. J. Cancer. 1989; 60: 185–192.

278. Minn A.J., Gupta G.P., Siegel P.M. Genes that mediate breast cancer metastasis to lung. Nature. 2005b; 436 (7050): 518–524. doi: 10.1038/nature03799.

279. Minn A.J., Kang Y., Serganova I., Gupta G.P., Giri D.D., Doubrovin M., Ponomarev V., Gerald W.L., Blasberg R., Massague J. Distinct organ-specific metastatic potential of individual breast cancer cells and primary tumors. J Clin Invest 2005a; 115: 44–55.

280. Moazzami B., Chaichian S., Farahvash M.R., Taheri S., Ahmadi S.A., Mokhtari M., Sheibani K. A Rare Case of Gestational Gigantomastia with Hypercalcemia: The Challenges of Management and Follow up. J Reprod Infertil. 2016 Oct-Dec; 17 (4): 243–246.

281. Modarressi T., Levine M.A., Tchou J., Khan A.N. Gestational Gigantomastia Complicated by PTHrP-Mediated Hypercalcemia. Journal of Clinical Endocrinology & Metabolism. 2018; 103 (9): 3124-3130. DOI: 10.1210/jc.

282. Moller U.K., Streym S., Mosekilde L., Heickendorff L., Flyvbjerg A., Frystyk J., Jensen L.T., Rejnmark L. Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study. Osteoporos Int. 2013 Apr; 24 (4): 1307-20. doi: 10.1007/s00198-012-2062-2.

283. Moraes R.C., Zhang X., Harrington N., Fung J.Y., Fu M.F., Hilsenbeck S.G., Allred D.C., Lewis M.T. Constitutive activation of smoothened (SMO) in mammary glands of transgenic mice leads to increased proliferation, altered differentiation and ductal dysplasia. Development. 2007; 134 (6): 1231–1242. doi: 10.1242/dev.02797.

284. More C., Bettembuk P., Bhattoa H.P., Balogh A. The effects of pregnancy and lactation on bone mineral density. Osteoporos Int. 2001; 12: 732–737.

285. Muller A., Homey B., Soto H., Ge N., Catron D., Buchanan M.E., McClanahan T., Murphy E., Yuan W., Wagner S.N., Barrera J.L., Mohar A., Verastegui E., Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410 (6824): 50–56. doi: 10.1038/35065016.

286. Mundy G.R., Martin T.J. Pathophysiology of skeletal complications of cancer. In: Mundy G.R., Martin T.J., editors. Handbook of experimental pharmacology. Physiology and pharmacology of bone. Berlin: Springer-Verlag; 1993. Vol. 107. p. 641–67.

287. Mundy G.R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002; 2: 584–93.

288. Murray L.J., Abrams T.J., Long K.R., Ngai T.J., Olson L.M., Hong W., Keast P.K., Brassard J.A., O’Farrell A.M., Cherrington J.M., Pryer N.K. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer metastasis model. Clin Exp Metastasis 2003; 20: 757–66.

289. Nam J.S., Turcotte T.J., Yoon J.K. Dynamic expression of R-spondin family genes in mouse development. Gene Expr. Patterns. 2007; 7: 306-312.

290. Nemeth E.F., Steffey M.E., Hammerland L.G., Hung B.C., Van Wagenen B.C., DelMar E.G., Balandrin M.F. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. U. S. A. 1998; 95: 4040-4045.

291. Neophytou C., Boutsikos P., Papageorgis P. Molecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis. Front. Oncol. 2018; 8: 31. doi: 10.3389/fonc.2018.00031.

292. Neville M.C., Peaker M. Calcium fluxes in mouse mammary tissue in vitro: intracellular and extracellular pools. J. Physiol. (Lond.) 1982; 332: 497-517.

293. Nguyen D.X., Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet. 2007; 8 (5): 341–52. doi: 10.1038/nrg2101.

294. Nicolson G.L. Cancer metastases: tumour and host cell organ properties important in metastasis to specific organs. Biochim Biophys Acta 1988; 948: 175–224.

295. Okolowsky N., Furth P.A., Hamel P.A. Oestrogen receptor-alpha regulates non-canonical Hedgehog-signalling in the mammary gland. Dev. Biol. 2014; 391: 219–229. doi: 10.1016/j.ydbio.2014.04.007.

296. Okoumassoun L.E., Russo C., Denizeau F., Averill-Bates D., Henderson J.E. Parathyroid hormone-related protein (PTHrP) inhibits mitochondrial-dependent apoptosis through CK2. Journal of Cellular Physiology. 2007; 212: 591–599.

297. Okyay D.O., Okyay E., Dogan E., Kurtulmus S., Acet F., Taner C.E. Prolonged breast-feeding is an independent risk factor for postmenopausal osteoporosis. Maturitas. 2013; 74 (3): 270–275. doi: 10.1016/j.maturitas.2012.12.014.

298. Onishi T., Hayashi N., Theriault R. Future directions of bonetargeted therapy for metastatic breast cancer. Nat Rev Clin. Oncol. 2010; 7: 641–51.

299. Otieno B.A., Krause C.E., Jones A.L., Kremer R.B., Rusling J.F. Cancer Diagnostics via Ultrasensitive Multiplexed Detection of Parathyroid Hormone-Related Peptides with a Microfluidic Immunoarray. Anal Chem. 2016; 88 (18): 9269–9275. doi: 10.1021/acs.analchem.6b02637

300. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889; 1: 571–573.

301. Pai V.P., Marshall A.M., Hernandez L.L., Buckley A.R., Horseman N.D. Altered serotonin physiology in human breast cancers favors paradoxical growth and cell survival. Breast Cancer Res. 2009; 11 (6):R81. doi: 10.1186/bcr2448.

302. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner FL., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351: 2817-2826. 10.1056/NEJMoa041588.

303. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA: Cancer J. Clin. 2005, 55, 74–108.

304. Peng Y., Shi K., Wang L., Lu J., Li H., Pan S., Ma C. Characterization of Osterix protein stability and physiological role in osteoblast differentiation. PLoS One. 2013; 8 (2):e56451. doi: 10.1371/journal.pone.0056451.

305. Philbrick W.M., Wysolmerski J.J., Galbraith S., Holt E., Orloff J.J., Yang K.H., Vasavada R.C., Weir E.C., Broadus A.E., Stewart A.F. Defining the roles of parathyroid hormone-related protein in normal physiology. Physiol. Rev. 1996; 76: 127–173.

306. Phippard D.J., Weber-Hall S.J., Sharpe P.T. Naylor M.S., Jayatalake H., Maas R., Woo I., Roberts-Clark D., Francis-West P.H., Liu Y.H., Maxson R., Hill R.E., Dale T.C. Regulation of Msx-1, Msx-2, Bmp-2 and Bmp-4 during foetal and postnatal mammary gland development. Development. 1996; 122: 2729-2737.

307. Powell G.J., Southby J., Danks J.A., Stillwell R.G., Hayman J.A., Henderson M.A., Bennett R.C., Martin T.J. Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites. Cancer Res. 1991; 51: 3059–3061.

308. Pratap J., Javed A., Languino L.R., van Wijnen A.J., Stein J.L., Stein G.S., Lian J.B. The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion. Mol Cell Biol. 2005; 25: 8581–8591.

309. Pratap J., Lian J.B., Javed A., Barnes G.L., van Wijnen A.J., Stein J.L., Stein G.S. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev. 2006; 25: 589–600.

310. Pratap J., Wixted J.J., Gaur T., Zaidi S.K., Dobson J., Gokul K.D., Hussain S., van Wijnen A.J., Stein J.L., Stein G.S., Lian J.B. Runx2 transcriptional activation of Indian Hedgehog and a downstream bone metastatic pathway in breast cancer cells. Cancer Res. 2008; 68 (19): 7795–7802. doi: 10.1158/0008-5472.CAN-08-1078.

311. Prentice A. Calcium in pregnancy and lactation. Annu. Rev. Nutr. 2000; 20: 249-272.

312. Propper A.Y., Howard B.A., Veltmaat J.M. Prenatal morphogenesis of mammary glands in mouse and rabbit. Journal of mammary gland biology and neoplasia. 2013; 18: 93–104.

313. Prosperi J.R., Khramtsov A.I., Khramtsova G.F., Goss K.H. Apc mutation enhances PyMT-induced mammary tumorigenesis. PLoS One. 2011; 6:e29339. doi: 10.1371/journal.pone.0029339.

314. Prosser C.G., Farr V.C., Davis S.R. Increased mammary blood flow in the lactating goat induced by parathyroid hormone-related protein. Exp. Physiol. 1994; 79: 565-570.

315. Psaila B., Lyden D. The metastatic niche: Adapting the foreign soil. Nat. Rev. Cancer 2009; 9, 285–293.

316. Purrington K.S., Slager S., Eccles D., Yannoukakos D., Fasching P.A., Miron P. et al., Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis. 2014; 35 (5): 1012–9.

317. Qing H., Ardeshirpour L., Pajevic P.D., Dusevich V., Jahn K., Kato S., Wysolmerski J., Bonewald L.F. Demonstration of osteocytic perilacunar/canalicular
remodeling in mice during lactation. J Bone Miner Res. 2012; 27 (5):

318. Rabbani S.A., Khalili P., Arakelian A., Pizzi H., Chen G., Goltzman D. Regulation of parathyroid hormone-related peptide by estradiol:effect on tumor growth and metastasis in vitro and in vivo. Endocrinology 2005; 146: 2885-2894.

319. Rakha E.A., Reis-Filho J.S., Baehner F. Dabbs D.J., Decker T., Eusebi V., Fox S.B., Ichihara S., Jacquemier J., Lakhani S.R., Palacios J., Richardson A.L., Schnitt S.J., Schmitt F.C., Tan P., Tse G.M., Badve S., Ellis I.O. Breast cancer prognostic classification in the molecular era: the role of histological grade. Breast Cancer Res. 2010; 12 (4) [207]. doi: 10.1186/bcr2607.

320. Ratcliffe W.A., Thompson G.E., Care A.D., Peaker M. Production of parathyroid hormone-related protein by the mammary gland of the goat. J. Endocrinol. 1992; 133: 87-93.

321. Ratcliffe W.A. Role of parathyroid hormone-related protein in lactation. Clin. Endocrinol. (Oxf.). 1992; 37: 402–404.

322. Reinhardt T.A., Lippolis J.D., Shull G.E., Horst R.L. Null mutation in the gene encoding plasma membrane Ca2+-ATPase isoform 2 impairs calcium transport into milk. J Biol Chem. 2004; 279: 42369–42373.

323. Reinhardt T.A., Horst R.L. Ca2+-ATPases and their expression in the mammary gland of pregnant and lactating rats. Am. J. Physiol. 1999; 276:C796-C802.

324. Ren W., Liu Y., Wan S., Fei C., Wang W., Chen Y., Zhang Z., Wang T., Wang J., Zhou L. BMP9 Inhibits Proliferation and Metastasis of HER2-Positive SK-BR-3 Breast Cancer Cells through ERK1/2 and PI3K/AKT Pathways. PLoS ONE. 2014; 9 (5): e96816. https://doi.org/10.1371/journal.pone.0096816.

325. Riggi N., Aguet M., Stamenkovic I. Cancer metastasis: a reappraisal of its underlying mechanisms and their relevance to treatment. Annu Rev Pathol. 2018; 13: 117–140.

326. Robinson G.W., Karpf A.B., Kratochwil K. Regulation of mammary gland development by tissue interaction. J. Mammary Gland Biol. Neoplasia. 1999; 4: 9–19.

327. Robinson G.W. Cooperation of signalling pathways in embryonic mammary gland development. Nature reviews Genetics. 2007; 8: 963–972.

328. Robinson T.J., Liu J.C., Vizeacoumar F., Sun T., Maclean N., Egan S.E., Schimmer A.D., Datti A., Zacksenhaus E. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One. 2013; 8:e78641. doi: 10.1371/journal.pone.0078641.

329. Rodda C.P. Kubota M.J. Heath A. Ebeling P.R. Moseley J.M. Care A.D. Caple I.W. and Martin T.J. Evidence for a novel parathyroid hormone-r.elated protein in fetal lamb parathyroid glands and sheep placenta: comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy. J Endocrinol. 1988; 117: 261–271.

330. Rojano-Mejia D., Aguilar-Madrid G., Lopez-Medina G., Cortes-Espinosa L., Hernandez-Chiu M.C., Canto-Cetina T., Vergara-Lopez A., Coral-Vazquez R.M., Canto P. Risk factors and impact on bone mineral density in postmenopausal Mexican mestizo women. Menopause. 2011; 18 (3): 302–306. doi: 10.1097/gme.0b013e3181f2d3fb.

331. Rong H., Hydbring E., Olsson K., Burtis W.J., Rankin W., Grill V., Bucht E. Parathyroid hormone-related protein in neonatal and reproductive goats determined by a sensitive time-resolved immunofluorometric assay. Eur. J. Endocrinol. 1997; 136: 546-551.

332. Rong H., Tsai J.A., Pernow Y., Bucht E. Calcitonin-suppressed expression parathyroid hormone-related protein in breast cancer cells. Biochem. Biophys. Res. Commun. 1999; 65: 260-264.

333. Roodman G.D. Biology of osteoclast activation in cancer. Journal of Clinical Oncology 2001; 19: 3562–71.

334. Roodman G.D. Cell biology of the osteoclast. Exp Hematol. 1999; 27: 1229–41

335. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med. 2004; 350 (16): 1655–1664. doi: 10.1056/NEJMra030831.

336. Ross D.G.F., Smart C.E., Azimi I., Roberts-Thomson S.J., Monteith G.R. Assessment of ORAI1-mediated basal calcium influx in mammary epithelial cells. BMC Cell Biol. 2013; 14: 57.

337. Rostami R., Mittal S., Rostami P., Tavassoli F., Jabbari B. Brain metastasis in breast cancer: a comprehensive literature review. J Neurooncol. 2016; 127: 407–414. doi.org/10.1007/s11060-016-2075-3.

338. Rouffet J., Barlet J.P. Parathyroid hormone-related peptide (PTHrP) and bone metabolism. Arch Physiol Biochem. 1995; 103: 3–13.

339. Ryan B.A., Kovacs C.S. The puzzle of lactational bone physiology: osteocytes masquerade as osteoclasts and osteoblasts. J Clin Invest. 2019; 129 (8): 3041–3044. doi: 10.1172/JCI130640.

340. Sahin Ersoy G., Giray B., Subas S., Simsek E., Sakin O., Turhan O.T., Bulut S. Interpregnancy interval as a risk factor for postmenopausal osteoporosis. Maturitas. 2015; 82 (2): 236–240. doi: 10.1016/j.maturitas.2015.07.014.

341. Saito H., Tsunenari T., Onuma E., Sato K., Ogata E., Yamada-Okabe H. Humanized monoclonal antibody against parathyroid hormone-related protein suppresses osteolytic bone metastasis of human breast cancer cells derived from MDA-MB-231. Anticancer Res. 2005; 25 (6B): 3817–3823.

342. Salles J.P. Bone metabolism during pregnancy. Ann Endocrinol (Paris). 2016 Jun; 77 (2): 163-8. doi: 10.1016/j.ando.2016.04.004.

343. Sanders J.L., Chattopadhyay N., Kifor O., Yamaguchi T., Butters R.R., Brown E.M. Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines. Endocrinology. 2000; 141: 4357–64.

344. Santa Maria C., Cheng Z., Li A., Wang J., Shoback D., Tu C.L., Chang W. Interplay between CaSR and PTH1R signaling in skeletal development and osteoanabolism. Seminars in Cell & Developmental Biology. 2016; 49: 11–23. doi: 10.1016/j.semcdb.2015.12.004.

345. Santa-Maria C.A., Gradishar W.J. Changing treatment paradigms in metastatic breast cancer: lessons learned. JAMA Oncol. 2015; 1 (4): 528–534. quiz 549.

346. Satokata I., Ma L., Ohshima H. et al., Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat. Genet. 2000; 24: 391–395.

347. Savci-Heijink C.D., Halfwerk H., Koster J., van de Vijver M.J. A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat. 2016 Apr; 156 (2): 249-59. doi: 10.1007/s10549-016-3741-z.

348. Schade B., Lesurf R., Sanguin-Gendreau V. beta-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. Cancer Res. 2013; 73 (14): 4474–4487.

349. Scully O.J., Bay B.H., Yip G., Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics. 2012; 9 (5): 311–320.

350. Seitz P.K., Cooper K.M., Ives K.L. et al., Parathyroid hormone-related peptide production and action in a myoepithelial cell line derived from normal human breast. Endocrinology.1993; 133 (3): 1116–1124.

351. Seki K., Kato T., Sekiya S., Makimura N., Kudoh K., Furuya K., Nagata I. Parathyroid-hormone-related protein in human milk and its relation to milk calcium. Gynecol Obstet Invest. 1997; 44 (2): 102-6.

352. Sells Galvin R.J., Gatlin C.L., Horn J.W., Fuson T.R. TGF-? enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem Biophys Res Commun. 1999; 265: 233–9.

353. Selvamurugan N., Kwok S., Partridge N.C. Smad3 interacts with JunB and Cbfa1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. J Biol Chem. 2004; 279: 27764–27773.

354. Sever R., Brugge J.S. Signal transduction in cancer. Cold Spring Harb Perspect Med. 2015; 5 (4) pii: a006098. doi: 10.1101/cshperspect.a006098.

355. Sevrioukova I.F. Apoptosis-inducing factor: structure, function, and redox regulation. Antioxidants & redox signaling. 2011; 14: 2545–79.

356. Sharma B., Nannuru K.C., Saxena S., Varney M.L., Singh R.K. CXCR2: A Novel Mediator of Mammary Tumor Bone Metastasis. Int J Mol Sci. 2019 Mar 12; 20 (5). pii: E1237. doi: 10.3390/ijms20051237.

357. Shen X., Falzon M. PTH-related protein upregulates integrin alpha6beta4 expression and activates Akt in breast cancer cells. Exp Cell Res. 2006; 312: 3822–3834.

358. Shen X.L., Qian L., Falzon M. PTH-related protein enhances MCF-7 breast cancer cell adhesion, migration and invasion via an intracrine pathway. Exp. Cell Res. 2004; 294: 420-433.

359. Shennan D.B., Peaker M. Transport of milk constituents by the mammary gland. Physiol. Rev. 2000; 80: 925-951.

360. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018; 68 (1): 7–30.

361. Sihto H., Lundin J., Lundin M., Lehtimaki T., Ristimaki A., Holli K., Sailas L., Kataja V., Turpeenniemi-Hujanen T., Isola J., Heikkila P., Joensuu H. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res. 2011; 13 (5):R87. doi: 10.1186/bcr2944.

362. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309–19.

363. Sledge G.W. Jr., Miller K.D. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer. 2003 Aug; 39 (12): 1668-75.

364. Smid M., Wang Y., Zhang Y., Sieuwerts A.M., Yu J., Klijn J.G., Foekens J.A., Martens J.W. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008; 68: 3108-3114.

365. Southby J., Kissin M.W., Danks J.A., Hayman J.A., Moseley J.M., Henderson M.A., Bennett R.C., Martin T.J. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer. Cancer Res. 1990; 50: 7710–7716.

366. Sowers M.F., Hollis B.W., Shapiro B., Randolph J., Janney C.A., Zhang D., Schork A., Crutchfield M., Stanczyk F., Russell-Aulet M. Elevated parathyroid hormone-related peptide associated with lactation and bone density loss. JAMA. 1996; 276 (7): 549-554. doi.org/10.1001/jama.1996.03540070045029.

367. Sowers M., Zhang D., Hollis B.W., Shapiro B., Janney C.A., Crutchfield M., Schork M.A., Stanczyk F., Randolph J. Role of calciotrophic hormones in calcium mobilization of lactation. Am. J. Clin. Nutr. 1998;
67: 284-291.

368. Sterling J.A., Oyajobi B.O., Grubbs B., Padalecki S.S., Munoz S.A., Gupta A., Story B., Zhao M., Mundy G.R. The hedgehog signaling molecules Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells. Cancer Res. 2006; 66: 7548–7553. doi: 10.1158/0008-5472.CAN-06-0452.

369. Stewart A.F., Cain R.L., Burr D.B. Jacob D., Turner C.H., Hock J.M., Drezner M.K. Six-month daily administration of parathyroid hormone and parathyroid hormone-related protein peptides to adult ovariectomized rats markedly enhances bone mass and biomechanical properties: a comparison of human parathyroid hormone 1–34, parathyroid hormone-related protein 1–36, and SDZ-parathyroid hormone 893. J. Bone Miner. Res. 2000; 15: 1517–1525.

370. Stewart A.F., Wu T., Burtis W.J., Weir E.C., Broadus A.E., Insogna K.L. The relative potency of a human tumor-derived PTH-like adenylate cyclase-stimulating preparation in three bioassays. J. Bone Miner. Res. 1987; 2: 37–43.

371. Stewart A.F. Hyperparathyroidism, humoral hypercalcemia of malignancy, and the anabolic actions of parathyroid hormone and parathyroid hormone-related protein on the skeleton. J Bone Miner Res. 2002; 17: 758–762.

372. Suda T., Takahashi N. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999; 20: 345–357.

373. Sugimoto T., Shiba E., Watanabe T. and S. Takai S. Suppression of parathyroid hormone-related protein messenger RNA expression by medroxyprogesterone acetate in breast cancer tissues. Breast Cancer Res. and Treatment 1999; 56: 11–23.

374. Surowiak P., Dziegiel P., Matkowski R., Sopel M., Wojnar A., Kornafel J., Zabel M. Prognostic value of immunocytochemical determination of parathyroid hormone-related peptide expression in cells of mammary ductal carcinoma. Analysis of 7 years of the disease course. Virchows Arch. 2003; 442: 245-251.

375. Suva L.J., Brander B.E., Makhoul I. Update on bone-modifying agents in metastatic breast cancer. Nat Rev Endocrinol. 2011 May 24; 7 (7): 380-1. doi: 10.1038/nrendo.2011.80.

376. Suva L.J., Washam C., Nicholas R.W., Griffin R.J. Bone metastasis: mechanisms and therapeutic opportunities. Nat Rev Endocrinol. 2011; 7 (4): 208–218. doi: 10.1038/nrendo.2010.227.

377. Suvannasankha A., Chirgwin J.M. Role of bone-anabolic agents in the treatment of breast cancer bone metastases. Breast Cancer Res. 2014; 16 (6): 484. doi: 10.1186/s13058-014-0484-9.

378. Suzuki Y., Tokuda Y., Saito Y., Umemura S., Osamura R.Y. Clinicopathological correlation between expression of PTHrP receptor and various prognostic factors in breast cancer without axillary lymph node metastasis. Tokai J Exp Clin Med. 2005 Jul; 30 (2): 127–32

379. Swan K.L., Wysolmerski J.J. in Endocrinology: Adult and Pediatric (Seventh Edition). Charter 64-Hypercalcemia of Malignancy. 2016; Pages 1125-1134.

380. Tabaries S., Dong Z., Annis M.G., Omeroglu A., Pepin F., Ouellet V., Russo C., Hassanain M., Metrakos P., Diaz Z., Basik M., Bertos N., Park M., Guettier C., Adam R., Hallett M., Siegel P.M. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene. 2011; 30: 1318–1328. doi: 10.1038/onc.2010.518.

381. Tahan S.R., Neuberg D.S., Dieffenbach A., Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer. 1993 Jun 1; 71 (11): 3552-9.

382. Taherian-Fard A., Srihari S., Ragan M.A. Breast cancer classification: Linking molecular mechanisms to disease prognosis. Brief Bioinform. 2015; 16: 461–474. doi: 10.1093/bib/bbu020.

383. Takagaki K., Takashima T., Onoda N., Tezuka K., Noda E., Kawajiri H., Ishikawa T., Hirakawa K. Parathyroid hormone-related protein expression, in combination with nodal status, predicts bone metastasis and prognosis of breast cancer patients. Exp Ther Med. 2012; 3 (6): 963–968. doi: 10.3892/etm.2012.521.

384. Tavassoli F.A., Devilee P.: World Health Organization classification of tumours. Pathology and Genetics Tumours of the Breast and Female Genital Organs. 2003. Lyon: IARC Press. Breast Cancer Res 2004; 6 133 19-23. doi.org/10.1186/bcr788.

385. Taylor M.S., Knowlton K.F., McGilliard M.L., Swecker W.S., Ferguson J.D., Wu Z., Hanigan M.D. Dietary calcium has little effect on mineral balance and bone mineral metabolism through twenty weeks of lactation in Holstein cows. J Dairy Sci. Elsevier; 2009; 92: 223–37. 10.3168/jds.2008-1345.

386. Teti A., Zallone A. Do osteocytes contribute to bone mineral homeostasis? Osteocytic osteolysis revisited. Bone. 2009; 44 (1): 11–16.

387. Thiede M.A. Parathyroid hormone-related protein: a regulated calcium-mobilizing product of the mammary gland. J Dairy Sci. 1994; 77 (7): 1952–1963.

388. Thiede M.A. and Rodan, G. A. Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue. Science. 1988; 242: 278-280.

389. Thomas R.J., Guise T.A., Yin J.J., Elliott J., Horwood N.J., Martin T.J., Gillespie M.T. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 1999; 140: 4451–8.

390. Toribio R.E., Brown H.A., Novince C.M., Marlow B., Hernon K., Lanigan L.G., Hildreth B.E.III, Werbeck J.L., Shu S.T., Lorch G., Carlton M., Foley J., Boyaka P., McCauley L.K., Rosol T.J. The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J. 2010; 24 (6): 1947–1957.

391. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65 (2): 87–108.

392. Torres D.A., Freitas M.B., Goncalves R.V. Changes in bone turnover and calcium homeostasis during pregnancy and lactation in mammals: a meta-analysis. Reprod Fertil Dev. 2018 May; 30 (5): 681-688. doi: 10.1071/RD17163.

393. Torres D.A., Freitas M.B., da Matta S.L.P, Novaes R.D., Goncalves R.V. Is bone loss a physiological cost of reproduction in the Great fruit-eating bat Artibeus lituratus? PLoS One. 2019 Mar 28; 14 (3):e0213781. doi: 10.1371/journal.pone.0213781.

394. Torricelli C., Fortino V., Capurro E., Sacchi G., Ponzo P., Pacini A., Muscettola M., Maioli E. Role of PTHrp and PTHrp-engaged pathways in MCF-7 cells migration/invasion. Matrix Biol. 2006; 25: 104–111.

395. Tov A.B., Mandel D., Weissman Y., Dollberg S., Taxir T., Lubetzky R. Changes in serum parathyroid hormone-related protein in breastfed preterm infants. Breastfeed Med. 2012 Feb; 7 (1): 50-3. doi: 10.1089/bfm.2010.0101.

396. Tovar Sepulveda V.A., Shen X., Falzon M. Intracrine PTHrP protects against serum starvation-induced apoptosis and regulates the cell cycle in MCF-7 breast cancer cells. Endocrinology. 2002; 143: 596–606.

397. Tran T., Utama F., Sato T., Peck A., Langenheim J., Udhane S., Sun, Y., Liu C., Girondo M., Kovatich A., Hooke J., Shriver C., Hu H., Palazzo J., Bibbo M., Auer P., Flister M., Hyslop T., Mitchell E., Chervoneva I. Rui H. Loss of Nuclear Localized Parathyroid Hormone-Related Protein in Primary Breast Cancer Predicts Poor Clinical Outcome and Correlates with Suppressed Stat5 Signaling. Clin Cancer Res. 2018; 24 (24): 6355-6366. DOI: 10.1158/1078-0432.CCR-17–3280.

398. Tsurimoto T. PCNA, a multifunctional ring on DNA. Biochim Biophys Acta. 1998 Nov 26; 1443 (1–2): 23–39.

399. Tsvetov G., Levy S., Benbassat C., Shraga-Slutzky I., Hirsch D. Influence of number of deliveries and total breast-feeding time on bone mineral density in premenopausal and young postmenopausal women. Maturitas. 2014; 77 (3): 249–254. doi: 10.1016/j.maturitas.2013.11.003.

400. Uemura H., Yasui T., Umino Y. et al., Regulatory factors on parathyroid hormone-related peptide production by primary culture of lactating rat mammary gland. Horm Metab Res 2005; 37: 463–467.

401. Uemura H., Yasui T., Yoneda N. et al., Measurement of N- and C-terminal-region fragments of parathyroid hormone-related peptide in milk from lactating women and investigation of the relationship of their concentrations to calcium in milk // J. Endocrinol. – 1997. – Vol. 153, № 3. – P445-451.

402. Unar-Munguia M., Torres-Mejia G., Colchero M.A., Gonzalez de Cosio T. Breastfeeding mode and risk of breast Cancer: a dose-response meta-analysis. J Hum Lact. 2017; 33 (2): 422–434. doi: 10.1177/0890334416683676.

403. Van de Vijver M.J., He Y.D., van’t Veer L.J., Dai H., Hart A.A., Voskuil D.W., Schreiber G.J., Peterse J.L., Roberts C., Marton M.J., Parrish M., Atsma D., Witteveen A., Glas A., Delahaye L., van der Velde T., Bartelink H., Rodenhuis S., Rutgers E.T., Friend S.H., Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.

404. Van Heerden J.A., Gharib H., Jackson I.T. Pseudohyperparathyroidism secondary to gigantic mammary hypertrophy. Arch Surg. 1988; 123 (1): 80-2.

405. Van Herwijnen M.J., Zonneveld M.I., Goerdayal S., Nolte-’t Hoen E.N., Garssen J., Stahl B., Maarten Altelaar A.F., Redegeld F.A., Wauben M.H. Comprehensive Proteomic Analysis of Human Milk-derived Extracellular Vesicles Unveils a Novel Functional Proteome Distinct from Other Milk Components. Mol Cell Proteomics. 2016 Nov; 15 (11): 3412-3423. doi: 10.1074/mcp.M116.060426.

406. Van Houten J.N., Wysolmerski J.J. Low estrogen and high parathyroid hormonerelated peptide levels contribute to accelerated bone resorption and bone loss in lactating mice. Endocrinology. 2003; 144 (12): 5521-5529.

407. Van Winden A.W., van den Broek I., Gast M.C., Engwegen J.Y., Sparidans R.W., van Dulken E.J., Depla A.C., Cats A., Schellens J.H., Peeters P.H., Beijnen J.H., van Gils C.H. Serum degradome markers for the detection of breast cancer. J Proteome Res 2010; 9: 3781–8.

408. Van Wingerden J.J. Gigantomastia--definition and association with hypercalcaemia. J Plast Reconstr Aesthet Surg. 2009; 62 (1): 112–4; doi: 10.1016/j.bjps.2008.06.019.

409. Vanharanta S., Massague J. Origins of metastatic traits. Cancer Cell. 2013; 24: 410–421. doi: 10.1016/j.ccr.2013.09.007.

410. VanHouten J., Dann P., McGeoch G., Brown E.M., Krapcho K., Neville M., Wysolmerski J.J. The calcium-sensing receptor regulates mammary gland parathyroid hormone-related protein production and calcium transport. J Clin Invest. 2004; 113 (4): 598–608.

411. VanHouten J.N., Wysolmerski J.J. The calcium-sensing receptor in the breast. Best Pract. Res. Clin. Endocrinol. Metab. 2013; 27 (3): 403–414. doi: 10.1016/j.beem.2013.02.011.

412. VanHouten J.N., Dann P., Stewart A.F., Watson C.J., Pollak M., Karaplis A.C., Wysolmerski J.J. Mammary-specific deletion of parathyroid hormone–related protein preserves bone mass during lactation J Clin Invest. 2003; 112 (9): 1429–1436. https://doi.org/10.1172/JCI19504.

413. VanHouten J.N., Neville M.C., Wysolmerski J.J. The calcium-sensing receptor regulates plasma membrane calcium adenosine triphosphatase isoform 2 activity in mammary epithelial cells: a mechanism for calcium-regulated calcium transport into milk. Endocrinology. 2007; 148 (12): 5943–5954.

414. VanHouten J.N., Wysolmerski J.J. Transcellular calcium transport in mammary epithelial cells. J Mammary Gland Biol Neoplasia. 2007; 12: 223–235.

415. van’t Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;
415: 530–6.

416. Vargas S. Gillespie M.T. Poweli G.J. Southby J. Danks J.A. Moseley J.M. Martin T.J. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization. J Bone Miner Res. 1992; 7: 971-979.

417. Vargas Zapata C.L., Donangelo C.M., Woodhouse L.R., Abrams S.A., Spencer E.M., King J.C. Calcium homeostasis during pregnancy and lactation in Brazilian women with low calcium intakes: a longitudinal study, The American Journal of Clinical Nutrition. 2004; 80 (2): 417–422. https://doi.org/10.1093/ajcn/80.2.417

418. Veltmaat J.M., Mailleux A.A., Thiery J.P., Bellusci S. Mouse embryonic mammogenesis as a model for the molecular regulation of pattern formation. Differentiation. 2003; 71: 1–17.

419. Veltmaat J.M., Van Veelen W., Thiery J.P., Bellusci S. Identification of the mammary line in mouse by Wnt10b expression. Dev. Dyn. 2004; 229: 349–356.

420. Veltmaat J.M., Relaix F., Le L.T. Kratochwil K., Sala F.G., van Veelen W., Rice R., Spencer-Dene B., Mailleux A.A., Rice D.P., Thiery J.P., Bellusci S. Gli3-mediated somitic Fgf10 expression gradients are required for the induction and patterning of mammary epithelium along the embryonic axes. Development. 2006; 133: 2325-2335.

421. Villanueva J., Martorella A.J., Lawlor K., Philip J., Fleisher M., Robbins R.J., Tempst P. Serum peptidome patterns that distinguish metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and age. Mol Cell Proteomics. 2006; 5 (10): 1840-1852; DOI: 10.1074/mcp.M600229-MCP200.

422. Visvader J.E., Stingl J. Mammary stem cells and the differentiation hierarchy: current status and perspectives. Genes Dev. 2014; 28 (11): 1143–1158.

423. Walsh C.A., Bowler W.B., Bilbe G., Fraser W.D., Gallagher J.A. Effects of PTH on PTHrP gene expression in human osteoblasts: up-regulation with the kinetics of an immediate early gene. Biochem. Biophys. Res. Commun. 1997; 239: 155-159.

424. Wan L., Pantel K., Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat. Med. 2013; 19: 1450–1464. doi: 10.1038/nm.3391.

425. Wansbury O., Mackay A., Kogata N., Mitsopoulos C., Kendrick H., Davidson K., Ruhrberg C., Reis-Filho J.S., Smalley M.J., Zvelebil M., Howard B.A. Transcriptome analysis of embryonic mammary cells reveals insights into mammary lineage establishment. Breast Cancer Res. 2011; 13, R79.

426. Washam C.L., Byrum S.D., Leitzel K., Ali S.M., Tackett A.J., Gaddy D., Sundermann S.E., Lipton A., Suva L.J. Identification of PTHrP(12–48) as a plasma biomarker associated with breast cancer bone metastasis. Cancer Epidemiol Biomarkers Prev. 2013; 22 (5): 972–983. doi: 10.1158/1055-9965.EPI-12–1318-T.

427. Weaver S.R., Fricke HP., Xie C., Lipinski R.J., Vezina C.M., Charles J.F., Hernandez L.L. Peripartum Fluoxetine Reduces Maternal Trabecular Bone After Weaning and Elevates Mammary Gland Serotonin and PTHrP. Endocrinology. 2018 Aug 1; 159 (8): 2850-2862. doi: 10.1210/en.2018-00279.

428. Weigelt B., Baehner FL., Reis-Filho J.S: The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol. 2010; 220: 263-280. 10.1002/path.2629.

429. Weigelt B., Peterse J.L. Van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005; 5 (8): 591–602.

430. Weilbaecher K.N., Guise T.A., McCauley L.K. Cancer to bone: a fatal attraction. Nat. Rev. Cancer. 2011; 11: 411–25. doi: 10.1038/nrc3055.

431. Winter E.M., Appelman-Dijkstra N.M. Parathyroid Hormone-Related Protein-Induced Hypercalcemia of Pregnancy Successfully Reversed by a Dopamine Agonist. J Clin Endocrinol Metab. 2017; 102 (12): 4417-4420. doi: 10.1210/jc.2017-01617.

432. Wojcik S.F., Capen C.C., Rosol T.J. Expression of PTHrP and the PTH/PTHrP receptor in purified alveolar epithelial cells, myoepithelial cells, and stromal fibroblasts derived from the lactating rat mammary gland. Experimental Cell Research. 1999; 248 (2): 415-422. DOI: 10.1006/excr.1999.4435.

433. Wong M.H.; Pavlakis N. Optimal management of bone metastases in breast cancer patients. Breast Cancer Targets Ther. 2011; 3: 35–60.

434. Wu F., Zhang Y., Sun B., McMahon A.P., Wang Y. 2017. Hedgehog signaling: From basic biology to cancer therapy. Cell Chem. Biol. 24 (3): 252–280. doi: 10.1016/j.chembiol.2017.02.010.

435. Wulf G.G., Jurgens B., Liersch T., Gatzemeier W., Rauschecker H., Buske C., Hufner M., Hiddemann W., Wormann B. Reverse transcriptase/polymerase chain reaction analysis of parathyroid hormone-related protein for the detection of tumor cell dissemination in the peripheral blood and bone marrow of patients with breast cancer. J Cancer Res Clin Oncol. 1997; 123 (9): 514-21.

436. Wysolmerski J.J., Stewart A.F. The physiology of parathyroid hormone-related protein: an emerging role as a developmental factor. Annu. Rev. Physiol. 1998; 60: 431-460.

437. Wysolmerski J.J., McCaughern-Carucci J.F., Daifotis A.G., Broadus A.E., Philbrick W.M. Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development. Development. 1995;
121: 3539–3547.

438. Wysolmerski J.J. Parathyroid hormone-related protein: An update. Clin. Endocrinol. Metab. 2012; 97: 2947–2956.

439. Wysolmerski J.J., Cormier S., Philbrick W.M. Dann P., Zhang J.P., Roume J., Delezoide A.L., Silve C. Absence of functional type 1 parathyroid hormone (PTH)/PTH-related protein receptors in humans is associated with abnormal breast development and tooth impaction. J Clin Endocrinol Metab. 2001; 86: 1788–1794.

440. Wysolmerski J.J., Philbrick W.M., Dunbar M.E., Lanske B, Kronenberg H., Broadus A.E. Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development. Development 1998; 125 1285–1294.

441. Wysolmerski J.J. Interactions between breast, bone, and brain regulate mineral and skeletal metabolism during lactation. Ann NY Acad Sci. 2010; 1192: 161–169.

442. Wysolmerski J.J. Osteocytes remove and replace perilacunar mineral during reproductive cycles. Bone. 2013; 54 (2): 230–236.

443. Wysolmerski J.J., Broadus A.E., Zhou J., Fuchs E., Milstone L.M. and Philbrick W.M. Overexpression of parathyroid hormone-related protei in the skin of transgenic mice interferes with hair follicle development. Proc Nati Acad Sci U S A. 1994; 91: 1133-1137.

444. Yamamoto M., Duong L.T., Fisher J.E., Thiede M.A., Caulfield M.P., Rosenblatt M. Suckling-mediated increases in urinary phosphate and 3?,5?-cyclic adenosine monophosphate excretion in lactating rats: possible systemic effects of parathyroid hormone-related protein. Endocrinology. 1991; 129: 2614-2622.

445. Yan G., Huang Y., Cao H., Wu J., Jiang N., Cao X. Association of breastfeeding and postmenopausal osteoporosis in Chinese women: a community-based retrospective study. BMC Womens Health. 2019 Aug 13; 19 (1): 110. doi: 10.1186/s12905-019-0808-0.

446. Yang Y., Wang B. PTH1R-CaSR Cross Talk: New Treatment Options for Breast Cancer Osteolytic Bone Metastases. Int J Endocrinol. 2018; 2018: 7120979. doi: 10.1155/2018/7120979.

447. Yao B., Wang J., Qu S., Liu Y., Jin Y., Lu J., Bao Q., Li L., Yuan H., Ma C. Upregulated osterix promotes invasion and bone metastasis and predicts for a poor prognosis in breast cancer. Cell Death Dis. 2019 Jan 10; 10 (1): 28. doi: 10.1038/s41419-018-1269–3.

448. Yardley D.A. Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer. Breast Cancer (Dove Med Press). 2016 May 3; 8: 73-82. doi: 10.2147/BCTT.S97963.

449. Ye L., Bokobza S., Li J., Moazzam M., Chen J., Mansel R.E., Jiang W.G. Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells and correlates with poor prognosis in breast cancer. Cancer Science. 2010; 101: 2137-2144. doi: 10.1111/j.1349-7006.2010.01648.x.

450. Ye Y., Falzon M., Seitz P.K., Cooper C.W. Overexpression of parathyroid hormone-related protein promotes cell growth in the rat intestinal cell line IEC-6. Regulatory Peptides. 2001; 99: 169–174.

451. Ye L., Bokobza S.M., Jiang W.G. Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (Review). International Journal of Molecular Medicine. 2009; 24, 591-597. doi.org/10.3892/ijmm_00000269.

452. Yin J.J. Selander K. Chirgwin J.M., Dallas M., Grubbs B.G., Wieser, R., Massague J., Mundy G.R., Guise, T.A. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest. 1999; 103 (2): 197-206.

453. Yoneda T., Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun. 2005; 328: 679–687.

454. Yoshida A., Nakamura Y., Shimizu A., Harada M., Kameda Y., Nagano A., Inaba M., Asaga T., 2000. Significance of the parathyroid hormone-related protein expression in breast carcinoma. Breast Cancer Res. 2000; 7: 215-220.

455. Zabkiewicz C., Resaul J., Hargest R., Jiang W.G., Ye L. Bone morphogenetic proteins, breast cancer, and bone metastases: striking the right balance. Endocr Relat Cancer. 2017; 24 (10):R349–R366. doi: 10.1530/ERC-17-0139.

456. Zang W.J., Li H., Zhang Z.F., QuZhen R., CuoMu Y.Z., Zhang D.K., Luo J., Loor J.J., Zheng H.L. Serotonin induces parathyroid hormone-related protein in goat mammary gland. J Anim Sci. 2018 Mar; 96 (3): 1010–1016. doi: 10.1093/jas/skx023.

457. Zeng C., Guo X., Long J., Kuchenbaecker K.B., Droit A., Michailidou K., Ghoussaini M., Kar S., Freeman A., Hopper J.L., Milne R.L., Bolla M.K., Wang Q., Dennis J. et al., Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Res. 2016 Jun 21; 18 (1): 64. doi: 10.1186/s13058-016-0718-0

458. Zeni S., Weisstaub A., Di Gregorio S., De Ferrer P.R., De Portela M.L. Bone Mass Changes In Vivo during the Entire Reproductive Cycle in Rats Feeding Different Dietary Calcium and Calcium/Phosphorus Ratio Content. Calcif Tissue Int. 2003; 73: 594–600. 10.1007/s00223-002–1093-7.

459. Zhang H., Zhu W., Biskup E. et al., Incidence, risk factors and prognostic characteristics of bone metastases and skeletal-related events (SREs) in breast cancer patients: a systematic review of the real world data. J Bone Oncol. 2018; 11: 38-50.

460. Zhang R., Li J., Assaker G., Camirand A., Sabri S., Karaplis A.C., Kremer R. Parathyroid Hormone-Related Protein (PTHrP): An Emerging Target in Cancer Progression and Metastasis. Adv Exp Med Biol. 2019; 1164: 161–178. doi: 10.1007/978-3-030-22254-3_13.

461. Zhao C., Lou Y., Wang Y. et al., A gene expression signature-based nomogram model in prediction of breast cancer bone metastases. Cancer Med. 2019; 8 (1): 200–208. doi: 10.1002/cam4.1932.

462. Zheng H.L., Li H., Sun Y.S. et al., Parathyroid hormone-related peptide (PTHrP): prokaryotic expression, purification, and preparation of a polyclonal antibody. Genetics and Molecular Research, 2014, 13 (3): 6448–6454.

463. Zheng L., Zhu K., Jiao H., Zhao Z., Zhang L., Liu M., Deng W., Chen D., Zhi Yao Z., Xiao G. PTHrP Expression in Human MDA-MB-231 Breast Cancer Cells Is Critical for Tumor Growth and Survival and Osteoblast Inhibition. Int J Biol Sci. 2013; 9 (8): 830–841. doi: 10.7150/ijbs.7039.

464. Zheng W., Zhang B., Cai Q., Sung H., Michailidou K., Shi J., Choi J.Y., Long J., Dennis J., Humphreys M.K., Wang Q., Lu W., Gao Y.T., Li C., Cai H., Park S.K., Yoo K., Noh D.Y., Han W., Dunning A.M., Benitez J., Vincent D., Bacot F., Tessier D., Kim S.W., Lee M.H. et al., Common genetic determinants of breast-cancer risk in East Asian women: a collaborative study of 23 637 breast cancer cases and 25 579 controls. Hum Mol Genet. 2013; 22 (12): 2539–50. doi: 10.1093/hmg/ddt089.

465. Zhuang X., Zhang H., Li X., Li X., Cong M., Peng F., Yu J., Zhang X., Yang Q., Hu G. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol. 2017; 19: 1274-1285.

466. Zia M.K., Rmali K.A., Mansel R.E., Jiang W.G. Level of Expression of Parathyroid Hormone Related Protein and its Receptor in Human Breast Cancer and its Correlation with the Clinical Outcome. International Journal of Cancer Research. 2007; 3: 92–102. DOI: 10.3923/ijcr.2007.92.102.


Предлагаем вашему вниманию журналы, издающиеся в издательстве «Академия Естествознания»
(Высокий импакт-фактор РИНЦ, тематика журналов охватывает все научные направления)

«Фундаментальные исследования» список ВАК ИФ РИНЦ = 1,674